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ABSTRACT
Regular consumption of fish is associated with low morbidity and mortality from acute
and chronic cardiovascular disease in humans. Fish are known to contain high
concentrations of essential omega-3 (now referred to as n-3) polyunsaturated fatty acids
(n-3 PUFA) eicosapentaenoic acid (EPA 20:5 n-3) and docosahexaenoic acid (DHA
22:6n-3). Experimental studies modelling cardiovascular disease in animals show that
feeding fish oils provides many cardioprotective actions and those directly related to
heart function (prevention of fatal cardiac arrhythmias; preconditioning, heart rate
slowing, prevention of heart failure) are associated with the incorporation of the diet –
derived n-3 PUFA into myocardial membranes. Human red blood cell (RBC) membrane
EPA+DHA concentration has been found to correlate inversely with adverse
cardiovascular outcomes and is proposed as a cardiovascular risk factor (termed the
Omega-3 Index). The use of this readily obtained marker as a risk factor is based on the
premise that it reflects the composition of the myocardium at risk. However this is by
no means certain as, in animal tissues DHA is incorporated into myocardium well above
circulating levels with little EPA detectable, whereas EPA and DHA are better matched
within RBC membranes. There are large variations in relative concentrations of n-3
PUFA amongst other tissues in animals and in man. While there is a growing body of
data on human atrial tissue obtained during surgical procedures, and blood samples are
readily obtained, the limited data on the fatty acid composition of human ventricular
myocardium is largely from cadaveric samples. It remains to be confirmed that the
omega-3 index can be reliably used as a marker of the composition of the human
ventricle and therefore an indicator of risk of cardiac morbidity and mortality.
Objectives: To establish the fatty acid compositional profile of human ventricular
myocardium and the relationships between EPA+DHA in human RBC, atria and
ventricle.
Methods: This thesis combined two separate studies in which the fatty acid composition
of both atria and ventricles were analysed from fresh, donor hearts and freshly explanted
failing hearts, all made available through a heart transplant program, and right atrial
biopsy and red blood cells were analysed from subjects undergoing cardiac surgery.
Surgical subjects were additionally randomised to receive a daily supplement of 1g fish
oil or placebo, commencing at the time of pre-admission check (baseline). Blood
iv

samples were taken at baseline and blood and atrial samples were taken perioperatively.
Results: DHA was identified as the major n-3 PUFA in all tissues, with concentrations
significantly higher than EPA and the n-6 PUFA arachidonic acid (AA) and linoleic
acid (LA) were the predominant PUFA (left ventricle: DHA 4.60±1.50; EPA 0.69±0.33;
AA 22.95±2.97; LA 20.66±2.55 mean%±SD, N=38). Patterns of incorporation were
different in different tissue types however no differences were seen between biopsy
samples of right atria and donor right atria in the separate studies. Supplementation
with fish oil significantly elevated RBC and atrial biopsy EPA+DHA. Despite
variations in proportions of EPA and DHA from tissue to tissue and even greater
variations between subjects, the concentration of EPA+DHA always provided the best
tissue to tissue correlation within subjects. It was highly correlated between RBC and
right atria biopsy (r2 = 0.4, P=0.0004) and between right atria donor and left ventricle
donor (r2=0.7, P<0.0001). The heart failure study revealed significant increases in DHA
in myocardium associated with both age and the stress of heart failure.
Conclusions: This thesis has established that DHA is the main n-3 PUFA in human
heart as it is in animal studies, with a range that overlaps with unsupplemented and lowdose supplemented laboratory rat. The DHA concentration is elevated as an apparently
compensatory response to stressors and in response to dietary fish oil, as it is in animal
studies. With DHA commonly the main n-3 PUFA of table fish, but EPA the principle
n-3 PUFA provided as supplements in many clinical trials, establishing the pre-eminent
position of DHA amongst n-3 PUFA in human myocardium increases confidence in the
consistent human epidemiological studies associating usual fish consumption with
cardiovascular outcomes and in translating outcomes of animal studies to interpret
mechanisms of n-3 PUFA action in man. It also may provide some explanation for the
more variable outcomes of clinical trials.
Despite the consistent predominance of DHA over EPA and variations in their relative
concentrations in myocardium and RBC, this thesis has established that the omega-3
index provides the most robust correlations of red blood cells with human heart tissue
and can be regarded as a good indicator of myocardial membrane n-3 PUFA
composition, confirming its potential as a marker of cardiac-associated risk.
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Chapter 1

LITERATURE REVIEW

1

1.0. INTRODUCTION
The World Health Organisation in 2001 listed cardiovascular diseases as one of the
three neglected global epidemics, the greatest killer in developing countries, in decline
in Western countries but still a problem, straining government health budgets across the
globe (WHO, 2003). Australian records estimate 300,000 people having chronic heart
failure (HF) with 30,000 new diagnoses each year and 50% of new HF caused by
ischaemic heart disease (IHD) (Krum, et al., 2006). In 2001 the United States had
approximately 5 million people with HF and 500,000 persons with newly diagnosed HF
each year (ACC/AHA, et al., 2001). Modifiable heart disease risk factors include
smoking, hypercholesterolaemia, hypertension, diabetes, sedentary lifestyles, obesity
and the emergent importance of the Omega-3 Index (Harris, et al., 2004b); the Index is
a measure of red blood cell membrane (RBC) phospholipid fatty acids EPA+DHA
(EPA (eicosapentaenoic acid, 20:5n-31) plus DHA (docosahexaenoic acids, 22:6n-3))
concentrations. Harris and von Schacky have identified an Omega-3 Index of less than
4% to signify a greater risk for cardiovascular diseases (CVD) death and an Omega-3
Index greater than 8% with the lowest risk of CVD death.
Correlations between red blood cell EPA+DHA and human myocardial EPA+DHA has
been difficult to obtain; the myocardial biopsy has been taken during corrective cardiac
surgery for valve replacement and /or coronary artery bypass from the right atria (Garg,
et al., 2006; Metcalf, et al., 2007) or the right interventricular septum at a 6-month postheart transplantation check-up for rejection (Harris, et al., 2004a). However, these
samples were obtained from disease affected hearts, either heavily influenced by anti-

1

n-, is the current IUPAC notation used to describe the location of the first double bond in the carbon
chain from the terminal or omega (ω) end of the particular fatty acid of interest. Fatty acids are designated
by chain length : number of double bonds.
2

rejection drugs or from a life-time of cardiac disease. There is a lack of evidence to the
nature of myocardial membrane phospholipid fatty acid composition in the disease-free
human heart furthermore; there is a lack of evidence profiling all four chambers of the
myocardium from viable normal myocardium or a failing heart. While there is some
data correlating red blood cell fatty acid composition to heart via atria, there is no data
validating the relationship between atria and ventricles. It is principally the ventricle
that is of interest in HF or as substrate for fatal cardiac arrhythmias.
To confidently utilise the Omega-3 Index as a risk factor for CVD, the fundamental
question needs answering as to whether the Index can be used to correctly reflect
EPA+DHA concentrations in membrane phospholipid fatty acids found in normal hearts
and failing hearts. This thesis will determine the reliability of using the right atrial
biopsies for EPA+DHA concentration comparisons with RBC EPA+DHA. Further this
thesis will fill in the gaps of knowledge regarding the membrane phospholipid fatty acid
composition of all four chambers of the human heart, both failing and normal. In so
doing it will determine the reliability of atrial samples reflecting the ventricle fatty acid
composition.

1.1. DIET AS A FACTOR MODULATING MEMBRANE FATTY
ACID COMPOSITION
Humans and other mammals lack the metabolic capacity to manufacture
polyunsaturated fatty acids de novo, therefore if needed, they must be obtained in the
diet (Clandinin, et al., 1991; Clandinin, 1997). Early last century, Burr established the
essentiality of dietary fats (linoleic acid, 18:2n-6, LA and arachidonic acid, 20:4n-6,
AA) in rodents for the prevention of disease (Burr, et al., 1929; Burr, et al., 1930).

3

Figure 1.1. Biosynthesis of the omega-3 and omega-6 PUFA.
Grey – n-3 PUFA; Black – n-6 PUFA. Desaturation of medium chain n-3 and n-6 PUFA, ALA
and LA, into the long and very-long chain fatty acids, 22:6n-3 (DHA) and 22:5n-6. At several
points in the formation of subsequent fatty acids there is competition for the same desaturase
enzymes, delta- 6 and delta-5 desaturase (δ-6 desat and δ-5 desat). Omega-3 PUFA are
preferentially desaturated (Stubbs, et al., 1984), however the enzymes can be overwhelmed by
the amount of n-6 PUFA available in the diet (Holman, et al., 1981). Furthermore, there is
limited conversion of ALA to the longer chain n-3 PUFAs, especially DHA in humans (Brenna,
2002). Preformed EPA and DHA in the diets are beneficial to avoid deficiencies (Burdge, et al.,
2005).

Today, the essential polyunsaturated fatty acids (EFA) are considered to be the n-6
PUFAs LA and AA (AHA, et al., 2009) and LA is commonly found in terrestrial seeds
and grains (Simopoulos, 1991; Gebauer, et al., 2006) of soy, corn and safflower.
Arachidonic acid is readily formed from LA (Figure 1.1), but there is no interconversion
between n-6 PUFA and n-3 PUFA, which must be obtained separately from the diet.
The n-3 PUFA alpha-linolenic acid (ΑLA; 18:3n-3) can be derived from terrestrial
plants (linseed, soy canola) and EPA and DHA consumed as fish. Alpha-linolenic acid
4

conversion to EPA or DHA in humans is limited (Brenna, 2002). One factor which can
be argued is the desaturase enzymes (delta-6 and delta-5 desaturase) being
overwhelmed by n-6 PUFA in the diet (Clandinin, 1997; Spector, 1999; Arterburn, et
al., 2006; Brenna, et al., 2009), and conversion of ALA to DHA is poor, in part because
of the competition between ALA and high basal intakes of LA but also because as
ALA in the diet increases, it will join with LA to compete with the intermediate 24:5 n3 for the delta-6 desaturase conversion to 24:6 n-3 and ultimately DHA (22:6 n-3)
(Figure 1.1). In contrast, one important animal study (Slee, et al., 2010) has shown rats
consuming human equivalent amounts of n-3 PUFA as FO, despite background diets
high in n-6 PUFA, are able to incorporate DHA into myocardial membranes
unimpeded. Support for preformed DHA consumption is strengthened (Jump, 2002;
Burdge, et al., 2005; Griffin, 2008; Barceló-Coblijn, et al., 2009; Brenna, et al., 2009)
and as shown for cardiovascular health, the type of polyunsaturated fat is more
important than the amounts of fat in the diet (Hu, et al., 2001; Cordain, et al., 2005).
Current dietary recommendation from the American Heart Association calls for 5-10%
of daily energy intake from n-6 PUFA (AHA, et al., 2009) with 1-2% of daily energy
intake from n-3 PUFA (WHO/FAO, 2004); equalling 1.5-3 g per day of ALA and 0.51.8 g per day of EPA and DHA (AHA, et al., 2002). The usual intake of the Australian
diet falls well short of that target (Meyer, et al., 2003) (see Appendices A & B).

1.2. HUMAN STUDIES
Alterations to the heart’s structural constituents can influence the heart’s
electrophysiology; the functioning of ion channels and pumps, and can alter blood flow
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to the myocardium causing ischaemia and infarction. These myocardial electrical
disturbances can possibly initiate heart failure characteristics and fatal arrhythmias.
Early associations linking diets to decreased

heart disease deaths was seen in

Norwegian families during the Second World War (Strom, 1948; Strom, et al., 1951).
Nelson found coronary heart disease patients lived longer (an extra 51 months) than
controls on a diet over 16-19years who included fish, at least 5 servings per week
(Nelson, 1972). The Framingham Study (Massachusetts, U.S.A.) (Dawber, et al., 1951;
Dawber, et al., 1957) reported high blood cholesterol levels as a significant risk factor
in morbidity and mortality in CVD and influentially directed the diet agenda of reducing
saturated fat and cholesterol containing foods in the diet for prevention and treatment of
heart disease in humans; with the addition to pharmacological measures.
Dyerberg and Bang’s observations of the low occurrence of ischaemic heart disease
amongst Inuit populations despite diets high in fat (Dyerberg, et al., 1975, 1989) came
during the 1970’s. Subsequent diet analysis identified the Inuit diet, sourced largely
from the sea, as being rich in the long-chain n-3 polyunsaturated fatty acids (n-3
PUFA), EPA and DHA (Bang, et al., 1980; Dyerberg, 1986) and one line of interest
focused on the identification of EPA as integral to the formation of the eicosanoids,
thromboxane-A3 (TXA3) and prostacyclin-I3 (PGI3); the 3-series being responsible for
the reduced incidence of platelet aggregation and thrombus formation (Dyerberg, et al.,
1978a; Dyerberg, et al., 1978b), with PGI3 acting upon the vascular endothelium by
stimulating a moderate vasodilatory action (Needleman, et al., 1979) in the prevention
of CVD. It was shown that Inuit diets were high in cholesterol when compared with
Danes (Table 1.1); comparable total fat intakes were seen also, despite less CVD deaths
(Bang, et al., 1971; Dyerberg, et al., 1975; Bang, et al., 1976; Bang, et al., 1980;
Dyerberg, et al., 1982; Dyerberg, et al., 1989).
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Table 1.1. Comparison of EPA and DHA1, 2 and cholesterol2 in Inuit and Danish
diet.
Fatty Acids

Greenland Inuit (Eskimos)

Danes

4.6

0.5

DHA

5.9

0.3

Total PUFA3

19

13

Omega-3 (g/day)

14

3

Omega-6 (g/day)

5

10

0.70

0.42

EPA3
3

Cholesterol (g/day)

EPA, eicosapentaenoic acid (20:5n-3); DHA, docosahexaenoic acid (22:6n-3).
2

1

Bang and

3

Dyerberg, 1980; Dyerberg, et.al., 1989. Simopoulos, 2002. Values are % of total fatty acids,
except where indicated.

Several longitudinal studies found inverse dose-response relationships to a reduction of
coronary heart disease deaths, with as little as 30-40 g of fish per week in the 20-year
Zutphen study, (Kromhout, et al., 1985). Long-term consumption compared to shortterm consumption of fatty fish, follow-up Zutphen study found a significant inverse
relationship and sudden cardiac death (SCD) independent of the total amount of fish
consumed (Streppel, et al., 2008). Clinically SCD is defined as “the unexpected natural
death due to a cardiac cause within a short time period from the onset of symptoms in a
person without any prior condition that would appear imminently fatal. It is most often
due to a sustained ventricular tachyarrhythmia” (Reynolds, et al., 2010). Shekelle and
colleagues re-examined their 25-year the Western Electric Study and found agreement
with Kromhout’s significant inverse association of fish consumption and reduced risk of
death from coronary heart disease (Shekelle, et al., 1985). The US Physicians Health
Study found that one serving of fish per week is preventative for SCD via its
antiarrhythmic effects on the heart (Albert, et al., 1998). Albert and colleagues also
noted an inverse association to whole blood n-3 PUFA and fish intake n-3 PUFA and
reduced risk for primary cardiac arrest death (Albert, et al., 2002).
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Using RBC membrane phospholipid fatty acids EPA plus DHA as a biomarker of
dietary intakes of seafood, Siscovick and colleagues of Seattle identified an inverse
relationship to reductions in SCD (Siscovick, et al., 1995). Results indicated that a
modest dietary amount of seafood, equal to one fatty fish meal per week or 5.5g of n-3
PUFA per month, was associated with a 50% reduction in primary cardiac arrest. RBC
EPA+DHA equal to 5% of total fatty acids were associated with a significant 70%
reduction in risk of primary cardiac arrest when compared to EPA+DHA 3% of total
fatty acids. Extending this study further, Siscovick highlighted that increasing fish
consumption beyond the modest amount of 5.5g EPA+DHA per month would not offer
a further reduced risk for primary cardiac arrest (Siscovick, et al., 2000).
In light of the then current animal research indicating antiarrhythmic properties of EPA
and DHA (McLennan, et al., 1988) reduced mortality from all-causes in recovered MI
patients identified the secondary protection benefits of introducing two or three fatty
fish meals per week in the Diet and Reinfarction Trial (DART) (Burr, et al., 1989). The
DART trial highlighted a clear separation between fish advice and no fish advice groups
at approximately 55-65 days (Figure 1.2); an argument for the initial delay from the
beginning of the trial to the separation of survival curves can be ascribed to a time lag in
which EPA and DHA can be adequately incorporated into the phospholipid membranes
of myocytes to affect cardioprotective benefits as described in later animal studies
(Owen, et al., 2004).
The Italian, Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico
Prevenzione trial (GISSI-P) is the second most significant secondary prevention postMI trial (Marchioli, et al., 1999). The GISSI-P clearly established from a daily
supplement of approximately 850 mg EPA and DHA per day relative risk for cardiac
death, coronary death and SCD were significantly reduced. There was no change in
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other deaths or non-fatal CV events however. Later time course analysis found early
benefits for consuming n-3 PUFA supplements, as survival curves significantly
diverged at 90 days for total mortality and at 120 days for SCD (Figure 1.3) (Marchioli,
2002). The GISSI-HF trial (2008) saw symptomatic, chronic heart failure patients
benefiting from additional treatment with FO (also approximately 850 mg EPA
and DHA) daily in addition to their usual care, although the time course for benefits in
was approximately 2 years (Tavazzi, et al., 2008b).

Figure 1.2. Increase in % survival from fish advice over a 2 year period in the
DART study.
Fish advice (upper trace) versus no fish advice (lower trace). The arrow indicates the time at
which dietary advice separation is seen in survival curves; approximately 55 - 65 days. Taken
from DART study of Burr, et al., 1989.

Cardiac

haemodynamics

(Mozaffarian,

2007)

and

electrographic

parameters

(Mozaffarian, et al., 2006b) are shown to be improved after dietary fish consumption or
FO supplementation; with DHA demonstrated as the bioactive fatty acid (Grimsgaard,
et al., 1998; Mori, et al., 1999). Modest reductions are seen in blood pressure (Morris,
et al., 1993; Mori, et al., 1999; Mozaffarian, et al., 2006a), heart rates (HR) (Mori, et
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al., 1999; Dallongeville, et al., 2003; Mozaffarian, et al., 2005b), slower atrioventricular
conduction and reduced longer QT intervals (Mozaffarian, et al., 2006b). Increased
significant inverse relationship with DHA incorporation into RBC phospholipids
(Mozaffarian, et al., 2008). In healthy volunteers increased heart rate variability (HRV)
in healthy men without known heart disease, have shown a positively associated with
serum cholesterol ester DHA (Brouwer, et al., 2002) and post-MI patients, FO
supplementation increased HRV also (Christensen, et al., 1997; Christensen, 2011).
However, a small study of selected human trials have shown no effect of n-3 PUFA on
various cardiac parameters (Geelen, et al., 2004).

Figure 1.3. Increase in % survival from fish advice over a 3.5 year period from the
2002 GISSI-P study.
Sudden death reduced in 120 days when compared with controls. The arrows along the
horizontal axis indicates the time (in days) at which the probability of increases in survival are
significantly demonstrated. Taken from GISSI-P Trial (Marchioli, 2002).

Lower concentrations of n-3 PUFA, especially DHA, were identified in association with
greater numbers of ventricular arrhythmias in patients with known potential fatal
arrhythmias and implanted cardioverter devices (ICD) (Christensen, et al., 2005). The
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prospective trial, The Study on Omega-3 Fatty Acids and ventricular Arrhythmia
(SOFA) indicated no significant differences between FO or control groups for the endpoints of appropriate ICD pacing or death. This trial found however, that patients with
a prior MI and taking FO did trend towards longer event-free survival (Brouwer, et al.,
2006b). Further, a subset of patients with ICD from the GISSI-HF trial, taking an oral n3 PUFA supplementation found a 20% reduction in activated ICD discharges; this result
was non-significant however (Finzi, et al., 2011). This line of investigation in the
effectiveness of co-treatment of patients with ICDs and n-3 PUFA is yet to be
thoroughly explored.
Atrial fibrillation (AF) occurs commonly in older individuals of sixty-five years and
more, occurring in about 5% of the Australian population (NHFA, 2008a), however
after cardiothoracic surgery, there is almost a 50% presentation after valvular surgery
and AF develops in 11 to 40% of patients after coronary artery bypass-grafting (CABG)
(Ommen, et al., 1997). A lesser number of patients with AF presentations are due to MI.
Atrial fibrillation can be added to the story of arrhythmias moderated by EPA and DHA
(Mozaffarian, et al., 2004; Reiffel, et al., 2006), however this is contested by others
(Frost, et al., 2005; Brouwer, et al., 2006a; Saravanan, et al., 2009). Due to its potential
for significant adverse events, recurrent or persistent AF is treated prophylactically with
pharmacological preparations (β-blockers, calcium-channel blockers, anti-inflammatory
and others) (Crystal, et al., 2002) or surgical ablation of the most common areas for
ectopic generation, for example the pulmonary veins (PV) (Haissaguerre, et al., 1998).
Ingestion of FO for one month prior to surgery, resulted in significantly longer effective
refractory periods than controls in the left and right superior PV and the left atrium,
resulting in reduced susceptibility to PV-initiated AF (Kumar, et al., 2011). Oral
intakes of tuna or other broiled or baked fish has been associated with lower incidence
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of AF and improve atrial function in older adults (Mozaffarian, et al., 2004). Cell
studies have shown isolated atrial myocytes reducing their induced asynchronous
contractions when acute administrations of EPA or DHA were given, the mechanism for
which has been purported to be the increased fluidity of the plasma membranes of these
cells (Jahangiri, et al., 2000). The efficacy of pre- and post-operative prophylactic
administration of EPA and DHA has been demonstrated in cardiac patients undergoing
CABG surgery with 15% of patients developing post-operative AF, compared to 33% in
the control group (Calò, et al., 2005). However, several recent studies have failed to
observe any benefit of fish oil supplementation in preventing post-operative AF
(Saravanan, et al., 2009; Heidarsdottir, et al., 2010; Farquharson, et al., 2011).
Docosahexaenoic acid is found in large concentrations in the membranes of the brain
and retina (Arterburn, et al., 2006) and is yet to be fully described in viable human
myocardium. The six double bonds in DHA provides a flexibility unmatched by other
fatty acids, and so disrupts cholesterol molecules from lateral packing within the
membrane bilayer construction and their protein interactions (Stillwell, et al., 2003).
Previously, human myocardial membrane phospholipid fatty acids have been
generalized from feeding studies in animals.
The last decade has provided numerous scientific reviews detailing positive associations
of fish and/or FO supplementation with significant benefits from heart disease and death
(Leaf, et al., 2003; Calder, 2004; Harris, et al., 2008b; Lee, et al., 2008; Duda, et al.,
2009; Lavie, et al., 2009; Von Schacky, 2009). Alternatively, several authors have
found no associations of beneficial effects from dietary fish or FO (EPA and DHA)
supplementation on the heart (Ascherio, et al., 1995; Morris, et al., 1995; Nakamura, et
al., 2005; Hooper, et al., 2006). Importantly however, several science advisories from
the U.S. (Kris-Etherton, et al., 2002; London, et al., 2007), Australia (NHFA, 2008c)
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and the United Kingdom (SACN, 2008), in addition to dietary guidelines from
governmental agencies (NHMRC, 2003; USFDA, et al., 2010) have supported the
consumption of fish and FO supplementation for heart health.

1.3. ANIMAL STUDIES
Animal heart studies clarified the relationships by which dietary fats altered myocardial
membranes, thus effecting change in myocardial membrane function.

Ready

modification of myocardial membranes by a 10% dietary cod liver oil (CLO) in rats was
first reported by Gudbjarnason and Oskarsdottir (Gudbjarnason, et al., 1977). The n-3
PUFA, DHA and EPA in CLO were avidly incorporated into membranes, whereas the
n-6 PUFA, AA and LA, were significantly reduced over the feeding period
(Gudbjarnason, et al., 1977) (Table 1.2). Additionally, DHA was shown to be
preferential incorporated into total phospholipids, and then the individual phospholipids
of phosphatidylcholine and phosphatidylethanolamine, of noradrenaline-stressed
myocardial cell membranes (Emilsson, et al., 1981). Again after CLO diets, fewer rats
experienced fatal ventricular fibrillation (VF) induced from repeated β-adrenoceptor
stimulation (isoproterenol injections) than controls (Benediktsdottir, et al., 1986).
Paradoxically, the endogenous stress of repeated adrenaline injections induced fatal
arrhythmias but also increased DHA incorporation in myocardial membranes in rats fed
a variety of diets differing in fat types (Benediktsdottir, et al., 1988). Even in CLO fed
rats, myocardial membrane compositions shifted to a more dominant DHA composition
over and above the diet induced increase and arrhythmias were inhibited
(Benediktsdottir, et al., 1988). Upon withdrawal of the stress, the membrane

13

phospholipid fatty acids returned to near normal baseline compositions (Benediktsdottir,
et al., 1988).
Table 1.2. Effect of 10% fat in the diet as cod liver oil1 compared to a control diet
in rats on selected heart membrane fatty acids.
Fatty Acids

Control

Cod Liver Oil

Relative change in
composition2

LA

30.4

20.6

⇓

AA

13.1

9.4

⇓

DHA

9.3

19.2

⇑⇑

Values are % of total fatty acids. AA, arachidonic acid (20:4n-6); LA, linoleic acid (18:2n-6);
DHA, docosahexaenoic acid (22:6n-3). 1.Gudbjarnason, et al., 1977, 1978. 2 ⇓ - Small decrease;
⇑⇑ - Large increase.

The functional consequences of membrane changes where reviewed by Gudbjarnason
(1975) and initially focused on the local cardiac effects of the prostaglandins:
increasing myocardial contractility; inhibit endogenous noradrenaline; coronary arterial
vasodilation; and antiarrhythmic effects (Gudbjarnason, 1975). The findings of ten
Hoor and de Deckere showed linoleic acid from sunflower seed oil increased
prostacyclin (PGI2) release and had positive influences on coronary flow, spontaneous
frequency and contractile force in rat (ten Hoor, et al., 1981). At this time the feeding of
linseed oil, high in ALA (18:3n-3) had no effect on flow, frequency or force in the rat
heart, but did halve prostacyclin production (ten Hoor, et al., 1981).
Abeywardena and colleagues (Abeywardena, et al., 1987) demonstrated in rat heart
studies the malleability of the cardiac membranes in dietary cross-over studies.
Myocardial membrane phospholipid fatty acids changed significantly to reflect the
principal fats in the diet (Table1.3). Thus, sunflower seed oil (SSO) supplying high
amounts of LA, increased AA concentrations, and tuna fish oil (FO) saw greater DHA
concentrations and suppression of the n-6 PUFA, LA and AA. Agreeing with the earlier
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work of Gudbjarnason (1975), DHA is seen to double in concentration from FO feeding
with EPA restricted to just detectable concentrations. When supplying large amounts of
EPA in the diet, Hock and colleagues (Hock, et al., 1987) still identify DHA as the
principal n-3 PUFA in myocardial membranes although EPA concentration is greatly
increased. These brief examples highlight that irrespective of the absolute amount of
total fat in the diet (12% or 5%), n-3 PUFA diets reduce both n-6/n-3 and AA/DHA
ratios, with DHA shown to be the principal n-3 PUFA in myocardial membrane PL fatty
acids.
Table 1.3. The effect of different diets on selected myocardial membrane
phospholipid fatty acids in rats.
Reference Saturated
High
High
Corn
Menhaden
Fatty Acids
Diet1
Fat2
SSO2
FO2
Oil3
Oil3
Saturated Fatty Acids
16:0 (PA)

10.6

9.4

9.3

9.9

12.6

14.6

18:0 (SA)

23.6

24.0

25.6

24.3

22.5

23.4

10.2

6.5

8.6

9.07

10.4

Monounsaturated Fatty Acids
18:1n-9 (OA)

7.9

Omega-6 Polyunsaturated Fatty Acids
18:2n-6 (LA)

21.3

13.7

17.8

9.1

20.2

8.2

20:4n-6 (AA)

16.9

18.9

19.3

15.0

23.6

11.5

Omega-3 Polyunsaturated Fatty Acids
20:5n-3 (EPA)

0.1

0.02

n.d.

0.9

0.1

6.4

22:5n-3 (DPA)

1.5

1.4

0.9

0.7

0.4

3.5

22:6n-3
(DHA)
n-6/n-3 Ratio

12.6

17.7

12.8

26.8

3.9

14.9

2.7

1.7

2.8

0.9

11.1

0.8

AA/DHA

1.3

1.1

1.5

0.6

6.1

0.8

Values are % of total fatty acids. n.d., not detected; Reference Diet, Commercial standard rat
chow; SSO, sunflower seed oil; FO, tuna fish oil; 16:0 (PA) palmitic acid; 18:0 (SA) stearic
acid; 18:1 (OA) oleic acid;18:2n-6 (LA) linoleic acid; 20:4n-6 (AA) arachidonic acid; 18:3n-3
(ALA) alpha-linolenic acid; 20:5n-3 (EPA) eicosapentaenoic acid;
22:5n-3 (DPA)
docosapentaenoic acid; 22:6n-3 (DHA) docosahexaenoic acid. 1 Charnock et al. 1986. 2
Abeywardena et al. 1987. 3 Hock et al. 1987.
15

McLennan in 1985 reported that modification of myocardial membranes, with dietary
PUFA, sunflower seed oil, altered rat heart function to be significantly anti-arrhythmic
in an in vivo model of MI (McLennan, et al., 1985). Extending the previous experiments
to whole animal model of arrhythmia and SCD, McLennan applied coronary vessel
occlusion (ischaemia) and reperfusion in tuna FO fed rats and significantly averted VF
in both conditions, however sunflower seed oil diets were effective against ischaemic
arrhythmias only (McLennan, et al., 1988). Billman and colleagues later confirmed
McLennan’s significant findings that FO prevented VF from occurring in exercising
dogs with a previous MI. In this experimental model, the dogs were not pre-fed EPA
and DHA, but an intravenous infusion of EPA and DHA was used (Billman, et al.,
1994). However, there is a high probability that the antiarrhythmic mechanisms for
dietary incorporated n-3 PUFA and acutely administered n-3 PUFA are not the same (as
summarised in (McLennan, 2004)). For example the infusion of n-3 PUFA in the dog is
accompanied by a large fall in heart rate, marked ECG changes and a high incidence of
heart block (Billman, et al., 1994) suggesting effects on electrical conduction pathways
that are not evident after dietary intervention. Most recently the dog was revealed to be
highly resistant to incorporation of DHA into myocardial membranes (Billman, et al.,
2012) (supplementary data) compared to rat or man, even after extremely high fish oil
supplementation, and may not be a good model for investigation of n-3 PUFA dietary
actions. Jordan and others, in a report for the U.S. Department of Health and Human
Services, summarised the experimental data and identified pre-fed FO in whole animals
(rats) as being more effective than n-6 PUFA in the prevention of ischaemia-induced
VF, and especially reperfusion-induced VF and total arrhythmic deaths. When
compared to pre-fed monounsaturated fats, DHA alone or EPA plus DHA significantly
reduced VF incidence; EPA alone did not significantly lower VF (Jordan, et al., 2004).
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An important development in cardioprotection from MI is that of ischaemic
preconditioning (IPC) (Murry, et al., 1986). An alternate to pharmacologic
preconditioning induction, Abdukeyum from the McLennan laboratory utilised a highDHA dietary supplement in rats to affect the protectiveness of IPC; limiting infarct size,
lethal myocardial cell injury and arrhythmia (Abdukeyum, et al., 2008). In whole
animal ischaemia-reperfusion studies, the myocardial membrane property of electrical
excitability/vulnerability is altered after different dietary fat feeding (saturated, n-6 and
n-3 diets) thence, altered membrane compositions (McLennan, et al., 1989). Fish oil
feeding leading to changes in membrane phospholipid fatty acids produces functional
benefits in rat hearts including anti-arrhythmic effects (McLennan, et al., 1988; Pepe, et
al., 1996), reduced fibrillation and sudden cardiac death after reperfusion (McLennan,
et al., 1989), reduced myocardial injury and improved contractility following ischaemia
and reperfusion (Pepe, et al., 1996; McLennan, 2001; Pepe, et al., 2002), lower resting
heart rates (McLennan, et al., 2005) and in female mice, hypertrophy is suppressed in
pressure-overloaded hearts (Huggins, et al., 2009). These animal studies are in accord
with Gudbjarnason (Gudbjarnason, 1975) where preferential increases in membrane
DHA corresponded to reductions in n-6 PUFA arachidonic acid (AA, 20:5n-6) and
linoleic acid (LA, 18:2n-6), though not proportionally. Other functional benefits to the
heart in animals from dietary n-3 PUFA include attenuation of cardiac hypertrophy
(Huggins, et al., 2009) and reducing myocardial oxygen consumption (Pepe, et al.,
2002).
In 2006, Reiffel highlighted the disparities in methodology of human clinical trials and
the inconsistency with which the results of these trials provide doubt towards the
antiarrhythmic effectiveness of dietary EPA and DHA, and questions whether the type
of dietary oil mattered (Reiffel, et al., 2006). It has been observed that the n-6 PUFA
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antiarrhythmic actions were lost when mixed with saturated fat (Charnock, et al., 1991;
McLennan, et al., 1993).

Importantly for translation to humans, Slee (2010) has

reported that on very low intakes, comparable to human dietary recommendations of 1-2
fish meals per week, FO impacts significantly on the incorporation of DHA into
myocardial membrane phospholipid fatty acids in the face of a high n-6 PUFA
background diet (Slee, et al., 2010). This study supports the previous reports of low
doses of dietary FO effecting myocardial membrane changes in DHA and EPA. Further,
Owen and colleagues (Owen, et al., 2004) found the myocardium of rats required only 2
days for significant changes to be observed in n-3 PUFA incorporation into the
membranes of the myocardium, particularly DHA, with a maximal effect achieved after
4 weeks. RBC membranes achieved significant changes in DHA and EPA after 4 weeks
(Owen, et al., 2004). Significantly, arrhythmia prevention was not evident until at least
7 days of feeding (McLennan 2001 Lipids), and isolated heart studies demonstrate that
membrane incorporation rather than circulating fatty acids provides arrhythmia
prevention (Pepe, et al., 1996; Abdukeyum, et al., 2008).
Different animal species exhibit different myocardial membrane PL fatty acids
compositions (Table 1.4). Notably whole hearts, ventricles and atrium display
differences in membrane PL fatty acid composition, however, it can been seen that the
fatty acid profiles demonstrate similarities such as DHA as the principal n-3 PUFA in
the whole heart, ventricles and atrium with the exception of the guinea pig heart. Alphalinolenic acid (ALA, 18:3n-3) and EPA are both found to be close to undetectable, in
many cases they are not reported. The n-6 PUFA are a significant proportion of total
fatty acids. There is a trend for LA to be greater in concentration than AA in the
ventricles of these animals shown here in Table 1.4. In the atrium AA is greater than
LA. Differentiations between the left side of the heart and the right side cannot be
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shown, which would shed light upon the functional differences imposed on the left and
right ventricles.
Different diets exhibit different myocardial membrane PL fatty acids compositions in
rats (Table 1.5). Notably 12% tuna FO more than doubles (the initially substantial)
DHA concentration in the whole heart and left ventricle, with 5% menhaden oil
increasing (initially very low) EPA by 32 times and marginally increasing DHA. The n6 PUFA, LA and AA, are suppressed in the tissues by FO and menhaden oils. When
diets high in n-6 PUFA, 12% sunflower seed (SSO) and 5% corn oils (CnO), are fed to
rats LA and AA are more evenly distributed when compared to a standard chow diet
which sees LA to be almost double that of AA. Corn oil reduces LA and increases AA
to near equal concentrations also, but to concentrations higher than SSO. A saturated fat
diet reduces LA and conserves AA, it also increases DHA and EPA is reduced to barely
detectable.

1.4. MYOCARDIAL MEMBRANE PHOSPHOLIPID FATTY ACIDS
OF THE HUMAN HEART
At autopsy, from the hearts of deceased persons whom died of sudden cardiac death
(SCD) (5 out of 8 cadaveric male human hearts) Gudbjarnason and Hallgrimsson first
identified a doubling of membrane DHA, with LA and AA reduced up to a third
(Gudbjarnason, et al., 1975a). To date a comprehensive presentation of the composition
of the human cardiomyocyte membrane phospholipid fatty acids remains elusive,
principally due to the difficulties in obtaining healthy viable tissue samples for analysis.
In the past twenty-five years there have been some reports of heart muscle lipid analyses
however, these heart samples have been associated with valve disease (Rocquelin, et al.,
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1985; Rocquelin, et al., 1989; Metcalf, et al., 2007), cardiac transplantation (Harris, et
al., 2004a), cardiomyopathy (Belfrage, et al., 1979), mitochondrial and microsomal
fractions (Gloster, et al., 1969, 1970), coronary artery bypass grafting surgery (Garg, et
al., 2006; Metcalf, et al., 2007; Metcalf, et al., 2010) and cadavers (Simon, et al., 1969;
Fletcher, 1972; Gudbjarnason, et al., 1975a; Gudbjarnason, et al., 1975b; Heckers, et
al., 1977; Gudbjarnason, et al., 1978c; Belfrage, et al., 1979; Ray, et al., 1979;
Gudbjarnason, 1980; Shenolikar, 1980; Ohlrogge, et al., 1981; Sen, et al., 1981; Sexton,
et al., 1995). These analyses are assumed to be the standard for the human heart,
however some samples are problematic, in particular the cadaveric samples due to the
varying times after death that these tissue samples have been harvested. Upon death
there is the loss of membrane integrity with autolytic changes occurring, with the
amount of cell damage and loss of fatty acids unknown (Gudbjarnason, et al., 1978c).
Systematic phospholipid fatty acid analysis of each chamber of the heart has not been
carried out in the human heart. The variety of analytical methods used to present each of
the above works, does not present a coherent story for today. The variety of results
therefore is reflected here by the limited numbers of fatty acids identified in some
papers seemingly for technical reasons (Gloster & Harris, 1969; Fletcher, 1972),
molecular phospholipid species identified (Gloster & Harris, 1970; Fletcher, 1972; Ray
& Sengupta, 1979; Sen & Sengupta, 1981), microsomal and mitochondrial results
(Gloster & Harris, 1969; Fletcher, 1972), very small sample numbers (n=1 or 2) (Simon
& Rouser, 1969; Gudbjarnason & Halgrimsson, 1975; Belfrage, 1979) and perplexing
results from a very small intraventricular catheter biopsy (questionable sample type –
possibly epithelium not muscle tissue) (Harris et al., 2004).
Anticipating the questions of relevance to the human condition, Gudbjarnason and
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Hallgrimsson provided phospholipid fatty acid data on several human hearts. Cadaveric
hearts, with deaths from SCD and MI, were to provide evidence of the same inverse
relationship of DHA to n-6 fatty acids as that found in their rat experiments. Further
relationships garnered from these results saw that increasing age brought increases in
myocardial membrane DHA (Gudbjarnason, 1980) and males were found to have higher
membrane DHA than females. The ratio of AA/DHA is proposed as a risk for SCD and
DHA is required for normal heart rate control (Gudbjarnason, et al., 1978c).
There has been one study that has given an understanding of the differences in fatty acid
concentrations in the atria and the ventricles of the rat heart (Charnock, et al., 1983).
There are no studies to date which report the membrane fatty acid composition of
normal human hearts, moreover, there are no studies that have differentiated the
regional differences in fatty acid composition between each atria or each ventricle of the
human heart.
Red blood cell membrane fatty acid, plasma and serum EPA and DHA are very good at
indicating a short term dietary profile. The Omega-3 Index which is the sum of EPA
and DHA in the membranes of red blood cells (RBC EPA+DHA), is proving valid for
the status of EPA+DHA in the human heart. An elevated Omega-3 Index, equal to or
more than 8.0 per cent is purported to be valid for heart health (Harris, et al., 2004b).
Most recently, a low Omega-3 Index has been associated with protection against VF
after sudden cardiac arrest (Aarsetoey, et al., 2011). The studies presented in this thesis
will show evidence for the normal composition of human heart phospholipid fatty acids,
show the close correlation between human red blood cell membrane phospholipids fatty
acids and human right atrium phospholipid fatty acids, and give evidence for the
correlation between red blood cell membrane fatty acids and human left ventricle
membrane fatty acids, particularly, the Omega-3 Index and left ventricular EPA+DHA.
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Table 1.4. Heart Membrane Phospholipid Fatty Acid Composition from Different Animal Species Consuming a Control Diet.
1

2

2
Rat
Rat
Atrium Ventricle

3

Rat
Left
Ventricle

Cat
Right
Ventricle

7

5

5

16.3

6.1

25.2

30.9

23.9

10.6

3.1

28.3

7.5

0.1

n.r.

n.r.

0.1

n.r.

n.r.

n.r.

n.r.

n.r.

n.d.

0.2

n.r.

n.r.

1.5

2.3

2.0

0.8

n.r.

0.3

n.r.

n.r.

12.6

3.5

3.4

0.3

24.2

0.3

n.r.

1.4

Marmoset 5Guinea
Ventricle Pig Heart

N=

12

13

11

11

26.7

13.5

24.9

21.3

15.0

21.8

24.6

15.4

21.1

15.9

16.9

18.0

16.9

n.d.

n.d.

n.d.

n.d.

n.d.

0.2

n.d.

n.d.

0.1

1.5

1.3

1.0

12.4

8.3

12.3

22:6n-3
(DHA)

Marmoset
Atrium

4

Rat
Heart

18:2n-6
(LA)
20:4n-6
(AA)
18:3n-3
(ALA)
20:5n-3
(EPA)
22:5n-3
(DPA)

9

Dog
Heart

4

Fatty
Acids

6

7
Mouse
Pig
Ventricle Heart

12

8

Values are % of total fatty acids. n.d., not detected; n.r., not recorded; 20:4n-6 (AA), arachidonic acid, 18:3n-3 (ALA), alpha-linolenic acid; 22:6n-3
(DHA), docosahexaenoic acid; 20:5n-3 (EPA), eicosapentaenoic acid; 18:2n-6 (LA), linoleic acid; 18:1 (OA), oleic acid; 16:0 (PA), palmitic acid; 18:0
(SA), stearic acid. 1Gudbjarnason, et al.,1978. 2Charnock, et al.,1983. 3Charnock, et al.,1985. 4Charnock, et al.,1985. 5Abedin, et al.,1999. 6Huggins et
al.,2009. 7Nair et al.,1999. 8Van der Vusse et al.,1982. 9Reibel et al.,1986.
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Table 1.5. The Effect of Different Diets on Heart Membrane Phospholipid Fatty
Acids in Rats.
Fatty
Acids
16:0
18:0
18:1
18:2n-6
(LA)
20:4n-6
(AA)
20:5n-3
(EPA)
22:5n-3
(DPA)
22:6n-3
(DHA)

Saturated
Fat1
9.4
24.0
10.2

High
SSO1
9.3
25.6
6.5

High
FO1
9.9
24.3
8.6

High SSO2
LV
9.4
26.6
5.6

High
FO2 LV
10.8
26.4
6.7

Corn
Oil3
12.6
22.5
9.07

Menhaden
Oil3
14.6
23.4
10.4

13.7

17.8

9.1

18.0

8.3

20.2

8.2

18.9

19.3

15.0

19.1

13.1

23.6

11.5

0.02

n.d.

0.9

n.d.

1.3

0.1

6.4

1.4

0.9

0.7

1.0

n.d.

0.4

3.5

17.7

12.8

26.8

11.2

26.8

3.9

14.9

Values are % of total fatty acids. n.d., not detected; LV, left ventricle; SSO, sunflower seed oil;
FO, tuna fish oil; AA, arachidonic acid; ALA, alpha-linolenic acid; LA, linoleic acid; EPA,
eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid. 1Charnock et
al.,1985. 2Charnock et al.,1986. 3Hock et al.,1987.

1.5. RESEARCH CONSIDERATIONS
As a model moves away from the clinical picture of human heart disease, researchers
need to balance five elements to complete a study; those elements include expertise,
time, cost, relevance and data/results (Figure 1.4). Heart research is dependent upon the
insights gained from animal studies however the principal weakness of animal
experiments is the direct extrapolation to the human condition. Numerous animal
models have been developed to explore the many facets of heart disease, such as heart
failure and hypertrophy. In the four year period 1993-1997, a total of 1943 papers on
heart failure and hypertrophy were produced (see review by Hasenfuss, 1998) utilising
numerous models of the disease and numerous animals; these included 18 different
types of rat model equaling 1028 papers, 6 rabbit, 11 dog, 3 pig, 2 guinea pig, 3 mouse,
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2 cat, 2 hamster, 1 turkey, 1 ferret, 3 sheep, 2 baboon and 1 bovine model, as well as 20
transgenic animal models (Hasenfuss, 1998).

Relevance Data Cost
Human hearts in vivo
Large mammalian hearts in vivo
Small mammalian hearts in vivo
Isolated perfused hearts
Isolated muscle preparations
Isolated cells
Subcellular fractions

Figure 1.4. The compromises of cost and clinical relevance versus experimental
value when investigating human heart disease.
This scheme identifies the difficulty of maintaining focus on research specificity when studying
the mechanisms of human heart disease. Diagram taken from Hearse and Sutherland (2000).

1.6. AIMS AND SIGNIFICANCE
The raft of information that is available from animal studies and the epidemiological
results give a clear indication that the n-3 PUFA, especially DHA, may be important for
a healthy and optimal heart function. Myocardial membranes of human hearts have been
investigated in previous studies using either cadaveric tissue or small atrial biopsy
samples but direct comparisons of phospholipid fatty acids from the atria and ventricles
is lacking.
There has been no clear evaluation of healthy human heart composition or comparison
of human failing and non-failing hearts to aid interpretation of epidemiological data or
to help establish the validity of experimental animal models.
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Aim 1a: To identify the major fatty acids in the healthy human heart to set the baseline
for investigation of relationship of fatty acid composition to heart function in health and
disease.
Aim 1b: To compare fatty acid composition of all heart chambers to establish the
validity of opportunistic atrial sampling as a marker of human heart composition.
Aim 1c:

To compare healthy and failing human heart fatty acid composition to

evaluate the impact of disease stress on heart fatty acid composition.
Significance 1: We have obtained viable samples of human myocardium from the left
and right atria, and left and right ventricles in an effort to define the composition of the
human heart in failing and healthy fresh heart tissue.
The composition of phospholipids, especially the sum of EPA and DHA in red blood
cell (RBC) membranes (the Omega-3 Index) has been proposed as a clinical biomarker
of cardiovascular health. With EPA+DHA values greater than 4.0% of total
phospholipids as an indicator of heart health.
Aim 2: To compare the fatty acid composition of human red blood cell and atria
Significance 2: Dietary evidence exists in numerous animal studies and limited human
studies of the direct effect of heart membrane incorporation of dietary eicosapentaenoic
and docosahexaenoic acids. Little research of comparisons of RBC EPA+DHA to atrial
membrane EPA+DHA in humans has been made, but the comparison of RBC
EPA+DHA to left ventricular membrane EPA+DHA is yet to be determined.
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1.7. RESEARCH QUESTIONS
Animal studies show fish oil fatty acids (EPA and/or DHA) in the diet are important,
but analysis shows DHA is the major contributor to heart myocyte membranes and n-3
PUFA has been shown to benefit experimental hypertrophy and heart failure. Human
epidemiological and diet intervention research show that the n-3 PUFA, EPA and DHA,
may be important for optimal healthy heart function and a poor dietary intake of fish,
hence poor in n-3 PUFA has been associated with an increased risk of cardiovascular
disease, including heart failure and sudden cardiac death (Siscovick, et al., 2000;
Albert, et al., 2002; Harris, et al., 2004b).
What is the fatty acid composition of atrial and ventricular myocardial membranes,
obtained from viable myocardium sourced from healthy and failing human hearts?
Could heart failure be associated with low n-3 polyunsaturated fatty acids in the
myocardial membrane? Are there differences between the left side of the heart and the
right side of the heart in consideration of the different workloads and stresses? Atrial
samples, as a readily accepted practice, are frequently obtained for medical diagnoses,
but do they reflect the composition of the ventricle?
Dietary incorporation of the long-chain n-3 polyunsaturated fatty acids can be readily
obtained from RBC and recently, atrial biopsy samples. Are the recent values found in
these studies likely to be a true reflection of left ventricular membrane long-chain n-3
polyunsaturated fatty acids? Can the Omega-3 Index be validated for the left ventricle?
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1.8. HYPOTHESIS
This study will test the hypothesis that human failing myocardial fatty acid composition
is different from the healthy heart. The difference may be adaptive to the condition or
the consequence of a nutritional (dietary) basis of the disorder. Results are interpreted in
light of controlled animal studies and a minimum of human study. It will further test the
hypothesis that (readily obtainable) red blood samples provide a valid and accurate
marker of (usually inaccessible) cardiac ventricular fatty acid composition.

1.9. THESIS OUTLINE
Chapter 1 presents a review of the literature supporting the basis for the detailed
investigation of normal human heart and failed human heart membrane phospholipid
fatty acids.
Chapter 2 will characterise atrial and ventricular samples from healthy human donor
and explanted failing human myocardium, and will additionally assess the relationship
between the atrium and ventricles in these same samples.
Chapter 3 will demonstrate the efficacy of the RBC EPA+DHA (the Omega-3 Index)
and right atrial membrane EPA+DHA comparisons and help to establish the Omega-3
Index as an integral part of a clinicians’ assessment of heart health in humans.
Chapter 4 will combine data from healthy human heart, identifying the correlation
between membrane omega-3 fatty acids of red blood cells, atrium and the left ventricle
as a basis for the final conclusions.
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Chapter 2

FATTY ACID COMPOSITION OF HUMAN HEART:
COMPARISON OF ATRIA AND VENTRICLE, AND
HEALTHY DONOR AND EXPLANTED (FAILING)
HEARTS

28

2.0. INTRODUCTION
The impetus for focusing much research on the influence of dietary fatty acids on the
heart arose from the initial observations by Dyerberg and Bang during the 1970’s of the
low occurrence of ischaemic heart disease amongst Inuit populations of the northwest
Greenland coast despite a diet high in cholesterol and animal fat (Dyerberg, et al., 1975,
1989). The Inuit diet was rich in the long-chain n-3 polyunsaturated fatty acids (n-3
PUFA), EPA (eicosapentaenoic acid, 20:5n-32) and DHA (docosahexaenoic acid,
22:6n-3), obtained largely from marine sources (Bang, et al., 1980; Abete, et al., 1999).
Dyerberg and Bangs’ observations directed much of the subsequent research interest
towards the prevention of cardiovascular diseases (CVD) from thrombus formation and
atherosclerosis (Dyerberg, et al., 1978a; Dyerberg, et al., 1978b). However, the Inuit
diet resulted in plasma cholesterol, triglyceride and lipoprotein fractions that were much
lower than habitual diets of Danes or, Inuit consuming a Danish diet.

The original diet-heart hypothesis that a high intake of dietary saturated fat induces
increases in serum cholesterol which leads to atherosclerosis and coronary heart disease
deaths (Keys, 1956; Keys, et al., 1957) has remained controversial for many years
(Bernard, et al., 1999; Taubes, 2001; Steinberg, 2004). A new diet-heart paradigm
(Siscovick, et al., 2003) focuses instead on the closer associations of dietary n-3 PUFA
to beneficial effects in the heart which has been supported by results from trials in postmyocardial infarction patients (Burr, et al., 1989; Valagussa, et al., 1999; Marchioli, et
al., 2002). However, the epidemiology linking fish consumption to prevention of fatal
arrhythmias (Gloster, et al., 1969; Bang, et al., 1972; Marchioli, et al., 2002), heart

2

n-, is the current IUPAC notation used to describe the location of the first double bond in the carbon
chain from the terminal or omega (ω) end of the particular fatty acid of interest. Fatty acids are designated
by chain length: number of double bonds.
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failure (Albert, et al., 2003; Mozaffarian, et al., 2005a; Tavazzi, et al., 2008a) and
lowering of the heart rate (Besse, et al., 1994; Mori, et al., 1999; Mozaffarian, et al.,
2005b; O’Keefe, et al., 2006) suggests mechanisms associated with much lower intakes
and for reduced cardiovascular mortality other than those classically associated with
ischaemic heart disease. Animal experimental studies have consistently demonstrated a
link between myocardial membrane fatty acid composition and heart function (Pepe, et
al., 1996, 2002; McLennan, et al., 2007; Abdukeyum, et al., 2008) underpinning fatal
arrhythmias (McLennan, 2004) and heart failure (McLennan, et al., 2012).

Docosahexaenoic acid is an important and unusual fatty acid in that it has the greatest
number of double bonds (six within its twenty-two carbon chain) found in mammalian
cell membranes. These double bonds provide a flexibility unmatched by other fatty
acids which disrupts cholesterol molecules from lateral packing within the cell
membrane bilayer construction and their protein interactions (al Makdessi, et al., 1995).
The other major n-3 PUFA EPA has been recognised for its potential role as a substitute
for AA in a variety of enzymatic and non-enzymatic pathways relating to bioactive
eicosanoids. More recently, DHA has been identified as a substrate for many of these
pathways leading to other bioactives (resolvins, protectins) that might also contribute to
the effects of fish oil (Serhan, et al., 2002). This fatty acid is found in large
concentrations in the membranes of specific vital organs, such as the brain and retina
(Arterburn, et al., 2006) and the hearts of several animals species.

As yet, the

membrane phospholipid fatty acids of the myocardium of humans are yet to be fully
described.

With DHA potentially to be the bioactive constituent in bestowing

cardioprotection against ischaemic arrhythmias (McLennan, et al., 1996), the membrane
phospholipid fatty acid composition of human cardiomyocytes is generalized from
feeding studies in animals.
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Heart membrane phospholipid fatty acid composition has been well characterised in
many animals; (with some examples given in Table 2.1) for rat (Gudbjarnason, et al.,
1978c; Charnock, et al., 1983; Reibel, et al., 1986); marmoset (non-human
primate)(Charnock, et al., 1983); guinea pig (Abedin, et al., 1999); mouse (Huggins, et
al., 2009); pig (Nair, et al., 1999); dog (van der Vusse, et al., 1982; Billman, et al.,
2010); and cat (Reibel, et al., 1986). All animals show altered cell membrane
composition in response to variation in dietary fatty acids. It is therefore often difficult
to know what the baseline is, as base diets will typically vary from laboratory to
laboratory. However, it is recognized that some basic differences arise between species
that can be characterised according to body surface area and metabolic rate. A major
finding is that the long-chain n-3 PUFA DHA is present in high concentrations in
myocardial membranes as animal body size decreases and metabolic rate increases.
From this observational comparative physiology it has been proposed that increased
DHA incorporation induces increased metabolic rate and increased heart rate (Bertrand,
et al., 2008). However, there is overwhelming evidence from both animal dietary
studies and human epidemiology, individual clinical trials and meta-analysis of clinical
trials with heart rate as secondary outcomes, that increasing dietary intake of DHA
(which in animals is clearly associated with increased myocardial DHA) actually slows
the heart rate (Mori, et al., 1999; Mozaffarian, et al., 2005b; Mozaffarian, et al., 2006b;
O’Keefe, et al., 2006; McLennan, et al., 2012). It is therefore suggested that rather than
causing increases in heart rate, myocardial DHA increases as an adaptive response to
increased metabolic rate (McLennan, et al., 2005). Furthermore, there is evidence of
adaptive increases in membrane DHA in animal models of cardiovascular stress
including pressure overload hypertrophy (Reibel, et al., 1986) and catecholamine stress
(Gudbjarnason, et al., 1975b; Benediktsdottir, et al., 1988). Adaptive increases in DHA
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are also recorded in skeletal muscle of man and rats, in response to exercise stress
independent of diet (Helge, et al., 1999; Helge, et al., 2001). This brings us to the
question of adaptive and/or dietary changes in the human heart.

While most data from animals comes from ventricular sections obtained fresh under
laboratory controlled sampling and storage conditions, much of the human data (Table
2.2) is obtained from samples taken from cadavers with varying causes of death
(including cardiac) and time delays after death (Fletcher, 1972; Gudbjarnason, et al.,
1975a; Belfrage, et al., 1979; Sexton, et al., 1995). Alternatively, most fresh tissue for
analysis is atrial (Harris, et al., 2004a; Garg, et al., 2006; Metcalf, et al., 2007; Metcalf,
et al., 2010) or papillary muscle biopsy (Rocquelin, et al., 1985; Rocquelin, et al., 1989)
taken as a secondary outcome during surgery, or ventricular endothelial biopsy taken to
monitor rejection in transplanted hearts (Harris, et al., 2004a). Great variation is seen
across the n-3 and n-6 PUFA of interest from these previous investigations and limited
to, when identified, a single heart chamber. It is unknown whether the variations are
related to the sample location (chamber) or collection conditions. Therefore translation
of animal data to clinical application is limited by the incomplete characterization of
human heart and lack of direct comparison of tissues.
In order to fill the gap in the knowledge base of human heart membrane phospholipid
fatty acid composition, this study evaluated the membrane fatty acid composition of all
four cardiac chambers within each heart using fresh myocardial samples. Samples were
freshly obtained from explanted failing hearts and from viable healthy donor hearts
made available through a heart transplant program.
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Table 2.1. Heart Membrane Phospholipid Fatty Acid Composition from Differing Animal Species Consuming Control Diets.
Selected Myocardial Membrane Phospholipid Fatty Acids
n-6 PUFA

n-3 PUFA

Author (year)
Gudbjarnason, et al., (1978)

Sample Type
Rat Heart

n
12

LA
26.7

AA
15.4

ALA
n.d.

EPA
0.2

DPA
1.5

DHA
12.4

Van der Vusse et al., (1982)

Dog Left Ventricle

5

25.2

28.3

n.r.

0.4

n.r.

0.5

Rat Atria

13

13.5

21.1

n.d.

n.d.

1.3

8.3

Rat Ventricle

11

24.9

15.9

n.d.

n.d.

1.0

12.3

Marmoset Atria

6

15.0

18.0

n.d.

n.r.

2.3

3.5

Marmoset Ventricle

6

21.8

16.9

0.1

n.r.

2.0

3.4

Reibel et al., (1986)

Cat Right Ventricle

5

18.8

14.8

n.r.

n.r.

1.8

14.4

Abedin,et al., (1999)

Guinea Pig

12

24.6

23.9

n.r.

n.r.

0.8

0.3

Pig

7

6.1

3.1

0.1

0.2

0.3

0.3

Huggins et al., (2009)

Mouse Ventricle

3-5

16.3

10.6

n.r.

n.d.

n.r.

24.2

Billman et al., (2010)

Dog Right Atria

6

n.r.

n.r.

n.r.

0.4

n.r.

0.6

Charnock, et al., (1983)

Charnock, et al., (1985)

Nair et al., (1999)

AA - arachidonic acid, 20:4n-6 ; ALA - alpha-linolenic acid, 18:3n-3; LA - linoleic acid, 18:2n-6; EPA - eicosapentaenoic acid, 20:5n-3; DPA docosapentaenoic acid, 22:5n-3; DHA - docosahexaenoic acid, 22:6n-3. n.d. - not detected; n.r. - not recorded. n = number per group.
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Table 2.2. A Review of Relevant Past Human Heart Membrane Studies
Selected Myocardial Membrane Phospholipid Fatty Acid (means±SD % of total)
Author (year)

Sample Type

n

n-6 PUFA
LA
AA

Gudbjarnason
and
Hallgrimsson (1975, 76)

Cadaveric

2

n.r.1

17.8

n.r.

n.r.

Gudbjarnason
(1978)

n-3 PUFA
EPA
DPA

Cadaveric

151

17.6±0.7

17.9±0.5

n.r.

Cadaveric Right
Ventricle

1
2

25.8
21.0

16.2
23.8

Cadaveric

50

9.9

Left Papillary
Muscle

M=29
F=24

Sexton et al. (1995)

Cadaveric

Harris et al. (2004)

DHA

Comments

n.r.

n.r.

AA/DHA ratio declines with age; Limited
fatty acids reported; small sample numbers

n.r.

n.r.

5.6±0.3

n.r.
n.r.

n.r.
n.r

n.r.
n.r.

8.5
10.4

n.r.

n.r.

n.r.

n.r.

n.r.

18.9±0.4
19.4±0.6

23.4±0.4
22.5±0.4

0.2±0.02
0.2±0.02

0.5±0.08
0.5±0.08

1.6±0.04
1.5±0.06

5.1±0.2
5.3±0.2

Chronic rheumatic heart disease; Male age
range 41-70 yr, Females age range: 0-80 yr

M=54
F=25

16.8±3.7
18.6±3.9

15.7±4.6
13.9±3.7

0.2±0.1
0.2±0.1

0.5±0.4
0.3±0.2

1.5±0.5
1.1±0.4

3.3±1.0
2.8±1.3

Hearts from cardiac and non-cardiac deaths;
Combined sex age range: 7-92 yr

Left
Interventricular
Septum

21

9.1±2.8

9.1±3.6

0.3±0.2

0.2±0.1

0.8±0.5

1.5±0.8

Routine biopsy post-heart transplant; Age
average 56 yr; Subject sexes Males=16,
Females=5

Garg et al. (2006)

Right Atrial
Appendage

9

16.9±0.8

21.9±1.8

0.1±0.1

0.8±0.3

2.1±0.15

6.7±1.2

CABG surgery; Age mean 60 yr; Males=8;
Control subjects.

Metcalf et al. (2007)

Right Atrial
Appendage

10

14.7±1.7

20.8±2.0

0.1±0.03

0.5±0.1

2.0±0.4

4.8±0.6

CABG surgery &/or valve replacement; Age
60.7±14.5 (mean±SD yr), Males=9

Metcalf et al. (2010)

Right Atrial
Appendage

61

14.5±1.5

19.9±1.8

0.2±0.1

0.7±0.3

1.9±0.4

5.6±1.4

CABG surgery &/or valve replacement;
Subjects from previous trial used here also

et

al.

Belfrage et al. (1979)

Shenolikar (1980)
Rocquelin et al. (1985)

1

ALA

Author note: DHA important in maintenance
of normal heart rate; DHA increases in with
age, LA decreases with age
Heart numbers are small; sex unknown.
Multiple samples taken from a single heart
15 hours post-mortem.
Tissue samples were fixed in formalin

n.r. - not reported; AA/DHA - Arachidonic acid/Docosahexaenoic acid; CABG - Coronary artery-bypass grafting; LA - Linoleic acid.
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2.1. METHODS
2.1.1. SUBJECTS
The donor hearts available for transplantation came from individuals from the
general community and were included in this study due to the unavailability of crossmatched recipients or the length of time for transplantation was exceeded, whilst the
heart remained hypothermic in the cardioplegic and preservation solution. The
explanted hearts (failing hearts) came from the patients on the heart transplant list.
See Appendix for full phospholipid fatty acid composition; donor and explanted
(failing) hearts.
There were no differences found between ages of human donor heart group (Table
2.3) (50.8±19.1 years) (means±SD) and human explanted heart group (Table 2.4)
(48.8±12.7 years), p=0.8646. Further results for individual ages will be as part of
grouped data; ages grouped into decades with exceptions as noted.

2.1.2. SAMPLES
Complete chamber sets comprising atria (left and right) and ventricle (left and right)
were obtained from explant hearts, n=25 and from donor hearts, n=18. The age and
gender distribution of donor and explant hearts are provided in Tables 2.3 and 2.4.
All heart samples were obtained through Dr Salvatore Pepe, Laboratory Head of the
Cardiac Surgical Research Laboratory, Alfred Hospital and the Baker Heart Research
Institute, Melbourne. Explanted failing heart tissue was used with the approval of the
Alfred Hospital Human Ethics Committee for Discarded Tissue Research. The nonfailing donor hearts were made available when excluded from transplantation and
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were approved for use in research by donor family consent and the Victorian Organ
Donation Service, Australian Red Cross (Canton, et al., 2011).

Table 2.3. Human Donor Hearts Gender and Age groups.
Ages1

1

Gender

(years)

N

Female

Male

10 - 29

3

0

3

30 - 49
50 - 59
60 - 69

2
5
4

1
2
1

1
3
3

70 - 79

2

0

2

Total

16

4 (25%)

12 (75%)

Heart ages grouped into decades except 10-29 years and 30-49 years.

Table 2.4. Human Explant (Failing) Hearts Gender and Age groups.
Ages1
(years)
10 - 29
30 - 49
50 - 59
60 - 69
70 - 79
Total
1

Gender
N
2
8
9
6
0
22

Female
0
1
1
1
0
3 (14%)

Male
2
7
8
2
0
19 (86%)

Heart ages grouped into decades except 10-29 years and 30-49 years.

2.1.3. SAMPLE PREPARATION AND FATTY ACID ANALYSIS
2.1.3.1. Human Heart Sample Preparation
i) Lipid Extraction
Ventricle and atria samples were stored at -80℃ until ready for analysis. A modified
Folch (Folch, et al., 1956) lipid extraction technique was employed. The atrial tissue
samples cleaned of obvious fatty material (20–50 mg wet weight) were homogenized
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by hand, using all-glass Ten Broeck homogenisers (Pyrex™ or Wheaton™) in 4 mL
of analytical grade chloroform:methanol (2:1, v/v); once homogenized the samples
were left to rotate overnight in a cool room at 3℃. To all solvents 0.01% (w/v)
butylated hydroxytoluene (BHT) was added to act as an antioxidant.
Following rotation, 2 mL of 1M H2SO4 was added and the sample tubes were shaken
vigorously for 60 seconds, then placed in a Hettich Rotina 38R benchtop centrifuge
and spun at 400g for 10 minutes. The top aqueous layer was removed and the bottom
non-aqueous layer was conserved to clean glass screw-top test-tubes, the residual had
a further 2 mL of 1M H2SO4 added, it was then shaken and centrifuged again for a
further 10 minutes. The process of conserving the non-aqueous layer was repeated
and added to the initial sample screw-top test-tubes.
To absorb any residual H2O from the isolated lipid samples, a small amount of
anhydrous sodium dithionite is added, after which the sample is filtered through
silane treated glass wool. The purified lipid samples were placed in a heat block
(average temperature of 25℃) and dried under a stream of nitrogen gas. Once dried
the samples were removed from heat block, reconstituted in 5 mL of hexane and
placed in the freezer ready for phospholipid separation.
ii) Phospholipid Fraction Isolation
To isolate the phospholipid fatty acid fraction, the samples were applied to silica
solid phase extraction (SPE) cartridges (Certified Sep-Pak™ SPE). Chloroform, 3 x
10 mL, was used to elute cholesterol esters and free fatty acids, then 3 x 10 mL
chloroform: methanol (4:1, v/v) was used to elute the triacylglycerides, leaving the
remaining phospholipids to be eluted from the silica cartridge with 3 x 10 mL
methanol wash.
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iii) Fatty Acid Methyl Ester (Fame) Formation
The phospholipid fatty acids were methylated to fatty acid methyl esters (FAME) in
preparation for gas chromatography. The samples were collected into clean screwtop tubes, placed in a heat block (average temperature of 25 ℃) and dried down
under nitrogen gas to pure lipid, to which 2 mL methanol: toluene (4:1, v\v) was
added. In a fumehood, whilst vortexing, 200 µL acetyl chloride was added, the
samples where then placed in the heat block for 60 minutes at 100 ℃. At the end of
60 minutes the samples were quickly removed from the heat block and rapidly
cooled in ice, to then be centrifuged at 4000 g for 10 minutes. The resultant lipid
layer was then pipette into clean deactivated borosilica glass vials, using 250 µL
glass inserts.
iv) Gas Chromatography and Quantification of Fatty Acid Methyl Esters
The fatty acid methyl esters were analysed by flame ionizing detector - gas
chromatography (FID-GC) using a Shimadzu GC-17A chromatograph with the
automated sample injection system, AOC-20i. The capillary column was a Varian
CP-Select™ CB for FAME (Middleburg, Netherlands; catalogue number: CP7419)
at 50 m x 0.25 µm x 0.25 mm (length x wall coating x internal diameter). For each
sample run, consisting of 10 to 25 samples, two FAME reference standards were
used (NuChek Prep, Elysian, MN, USA; catalogue number: GLC 673B and SigmaAldrich Qualitative F.A.M.E. Mix, C4-C24; catalogue number: 18919-1AMP)
(Figure 2.1). A 1µL sample was injected into the split system using hydrogen gas as
the carrier, with a temperature ramp function commencing at 170℃ and rising to
210℃ over 24 minutes. Ionizing detector results are graphically depicted as peaks
utilising the Shimadzu Chromatopac Class-VP™ Version 7.2.1 SP1 software.
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Figure 2.1. Typical chromatogram from FID-GC of the Sigma-Aldrich Qualitative FAME standard (C4-C24). Peaks are identified on the FAME
standard as shown here labelled and are used to identify sample analyte fatty acids. Signal strength on Y-axis and time in minutes on X-axis.
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2.1.4. CHEMICALS
All chemicals, solvents and laboratory consumables are of analytical grade supplied by
Crown Scientific Pty Ltd (Ebos Group Ltd., Minto, NSW), Sigma-Aldrich Corporation
(Castle Hill, NSW), Phenomenex Australia Pty Ltd (Pennant Hills, NSW), BOC Gases
Australia Ltd (North Ryde, NSW), Waters Corporation Australia (Rydalmere, NSW),
Wheaton Science Products (Wheaton Industries Inc., Millville, NJ, USA) and NuChek
Prep Inc. (Elysian, MN, USA).
2.1.5. STATISTICAL ANALYSIS
Data was analysed using Statistix 9 Analytical Software (Tallahassee, FL, USA) and
graphed using GraphPad Prism 5, Version 5.02 (GraphPad Software Inc., USA).
Statistical tests include summary descriptive two-sample T-test and paired-T-tests, and
general analysis of variance (ANOVA) with fixed factors and post hoc multiple
comparisons. When appropriate, linear regression and correlation analyses were
conducted on individual fatty acids. Significance was accepted at p<0.05. Descriptive
statistics are displayed as means and standard deviation (means±SD) or means and
standard error of means (means±SEM).

2.2. RESULTS
2.2.1. DONOR HEARTS
2.2.1.1. Atria
Donor heart atrial phospholipid fatty acids comprised mainly of PUFA (49%) (Table
2.5) with 34% SFA and 16% total MUFA (Figure 2.2). At 40% the n-6 PUFA were the
main PUFA with 21% AA and 17% LA compared to 6% DHA, which was the main n-3
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PUFA (Figure 2.3), far exceeding the concentration of EPA (0.7%) and DPA (2%). At
0.1% or less, ALA was often undetectable.
When comparing left and right atria (Table 2.5) there was a small but statistically
significant difference in the saturated fatty acid palmitic acid but no other differences
were evident.
2.2.1.2. Ventricles
Donor heart ventricular phospholipid fatty acids comprised mainly of PUFA (54%)
(Table 2.5) with 32% SFA and 14% total MUFA (Figure 2.2). At 46% total n-6 PUFA
were the main PUFA with 23% AA and 21% LA compared to 4% DHA which was the
main n-3 PUFA (Figure 2.3), less than 2% for DPA, less than 1% EPA and 0.2% ALA
(Table 2.5).
Donor ventricles showed only minor differences between right and left chamber walls,
with left being lower in total SFA and higher in total PUFA (Figure 2.2). Within the
PUFA, AA and total n-6 PUFA were at significantly higher concentrations in the left
ventricle (Table 2.5, Figure 2.3).
2.2.1.3. Atria versus Ventricles
Small differences between atria and ventricles were seen as significantly lower total
SFA and total MUFA and significantly increased total PUFA in the ventricles (Figure
2.2). In the ventricles, LA and AA were found at similar concentrations (~22%), with
LA significantly greater than atrial LA (17%) (Table 2.5). Ventricle total n-6 PUFA was
significantly greater than atria total n-6 PUFA (Figure 2.3). Significantly lower total n-3
PUFA (Figure 2.3), lower DHA and EPA+DHA were found in the ventricles compared
to atria (Table 2.5).
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Table 2.5. Major Membrane Phospholipid Fatty Acids from Donor Human Hearts.
DONOR

Left Atria

Right Atria

Left Ventricle

Right Ventricle

16

16

16

16

N=

Major Saturated Fatty Acids1 (% of total)
16:0 (PA)

17.53±1.42a

15.64±2.87b

14.46±0.60b

15.18±0.81b

18:0 (SA)

16.15±1.70

16.78±2.30

15.76±1.60

16.55±1.32

c

Total SFA

a

34.87±1.74

a,b

33.70±2.01

31.45±1.39

33.02±1.17b

Major Monounsaturated
16:1n-7 (PoA)

1.52±0.83a,b

2.48±1.20a

0.61±0.50b

2.05±1.81a

18:1n-9 (OA)

11.51±1.69a

10.78±1.89a,b

9.71±1.35b

10.10±1.59a,b

16.33±2.22a

15.90±1.97a

13.11±1.76b

14.78±1.86a,b

Total MUFA

Major n-6 Polyunsaturated
18:2 (LA)

17.41±1.97b

16.67±1.34b

21.64±2.04a

21.58±1.86a

20:4 (AA)

21.54±1.62b

22.52±1.91b

24.44±2.13a

22.20±2.36b

40.68±2.37c

41.28±2.10c

47.97±1.68a

45.58±1.87b

Total n-6

Major n-3 Polyunsaturated
18:3 (ALA)

0.13±0.07b,c

0.08±0.08c

0.21±0.07a

0.18±0.08a,b

20:5 (EPA)

0.63±0.31

0.74±0.30

0.75±0.39

0.61±0.32

22:5 (DPA)

1.98±0.45

2.15±0.41

1.94±0.43

1.75±0.46

a

b

a,b

5.17±1.51

6.12±2.08

4.42±1.23

4.06±1.13b

Total n-3

7.97±1.71a,b

9.12±2.24a

7.38±1.51b

6.62±1.42b

Total PUFA

48.65±2.76c

50.40±2.86b,c

55.34±1.31a

52.20±2.15b

5.81±1.74a,b

6.86±2.33a

5.17±1.56b

4.67±1.38b

AA:DHA ratio

4.2

3.7

5.5

5.5

DHA:DPA

2.8

3.0

2.4

2.5

22:6 (DHA)

EPA+DHA

1

AA, Arachidonic acid; ALA, a-linoleic acid; DHA, Docosahexaenoic acid; DPA,

Docosapentaenoic

acid;

EPA,

Eicosapentaenoic

acid;

LA,

Linoleic

acid.

MUFA,

Monounsaturated fatty acids; OA, Oleic acid; PA, Palmitic acid; PoA, Palmitoleic acid; PUFA,
Polyunsaturated fatty acids; SA, Stearic acid; SFA, Saturated fatty acids. Results are means±SD.
a, b

and c superscripts denote significant differences, p<0.05, between donor heart chambers.
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Major Fatty Acids Classes in
Human Donor Heart
(% of total fatty acids)
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Figure 2.2. Atrium compared to ventricles for total MUFA, total SFA and total
PUFA in Human Donor Hearts.
In human donor hearts differences were observed when upper and lower chambers were
compared for total monounsaturated, total saturated and total polyunsaturated fatty acids. Donor
atrium, open columns (◻) and donor ventricles, filled columns (◼). *means±SD are statistically

Polyunsaturated Fatty Acid Classes
in Human Donor Heart
(% of total fatty acids)

different, p<0.05.
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Figure 2.3. Atrium compared to ventricles for total n-3 PUFA and total n-6 PUFA
in Human Donor Hearts.
In human donor hearts differences are observed when upper and lower chambers were
compared for total n-3 PUFA and total n-6 PUFA. Donor atrium, open columns (◻
◻) and donor
ventricles, filled columns (◼).*means±SD are statistically different, p<0.05.
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2.2.2. EXPLANT (FAILING) HEARTS
2.2.2.1. Atria
Explant (failing) heart atrial phospholipid fatty acids comprised mainly of PUFA (48%)
(Table 2.6) with 35% SFA and 17% total MUFA (Figure 2.4). At 39% the n-6 PUFA
were the main PUFA with 20% AA and 18% LA compared to 6% DHA, which was the
main n-3 PUFA (Figure 2.5), far exceeding the concentration of EPA (0.7%) and DPA
(1.7%). At 0.2% or less, ALA was often undetectable.
In the left compared to right atria (details in Table 2.6), there was a higher but
statistically significant different concentration in total SFA and the saturated fatty acid
palmitic acid, with significant differences seen in lower monounsaturated fatty acid
palmitoleic acid and lower n-3 PUFA docosapentaenoic acid. No other significant
differences were evident.
2.2.2.2. Ventricles
Explant heart ventricular phospholipid fatty acids comprised mainly of PUFA (51%)
(Table 2.6) with 34% SFA and 15% total MUFA (Figure 2.4). At 43%, the total n-6
PUFA were the main PUFA with 21% AA and 20% LA, compared to 4.9% DHA which
was the main n-3 PUFA (Figure 2.5), less than 2% for DPA, less than 1% EPA and
0.22% for ALA (Table 2.6).
Explant ventricles showed only minor differences between left and right chamber walls,
with left being lower in total SFA and total MUFA and higher in total PUFA. Minor
differences are seen between chambers but no significant differences were evident
(Table 2.6).
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2.2.2.3. Atria versus Ventricles
Small differences between atria and ventricles were seen as significantly lower total
MUFA and significantly increased total PUFA in the ventricles (Table 2.6). In the
ventricles, LA and AA were found at similar concentrations (~20%), with LA
significantly greater than atria LA (18%) (Table 2.6). Ventricle total n-6 PUFA (43%)
(Table 2.6) was found to be significantly greater than atria total n-6 PUFA (39%). It was
found that total n-6 PUFA was significantly higher and total n-3 PUFA significantly
lower in ventricle (Figure 2.5), including lower DHA and EPA+DHA (Table 2.6).

2.2.3. HUMAN DONOR HEARTS COMPARED TO EXPLANTED HUMAN
HEARTS
2.2.3.1. Atria
There was a significantly lower relative concentration of total n-6 PUFA and total
PUFA in explanted atria than in donor atria, whereas total MUFA was higher in
explanted atria (p=0.0131) (Table 2.7). The individual n-6 PUFA arachidonic acid and
n-3 PUFA DPA were significantly lower in explanted than donor atria (Table 2.7). The
ratio of DHA/DPA in explanted atria (3.82±0.25) was significantly higher than in donor
atria (2.87±0.21) (p=0.0047) (Figure 2.6).
2.2.3.2. Ventricles
There was a significantly lower relative concentration of n-6 PUFA linoleic acid and
arachidonic acid, total n-6 PUFA and total PUFA in explanted ventricles than in donor
ventricles (Table 2.7). There was significantly lower relative concentration of n-3 PUFA
DPA in explanted ventricles but higher relative concentration of DHA (Table 2.7). The
ratio of DHA/DPA in explanted ventricles (3.32±0.23) was significantly higher than in
donor ventricles (2.44±0.16) (p= 0.0027) (Figure 2.7).
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Table 2.6. Major Membrane Phospholipid Fatty Acids from Explanted (Failing)
Human Hearts.
EXPLANTED
Left Atria
Right Atria
Left Ventricle Right Ventricle
N=

22

22

22

22

Major Saturated Fatty Acids1 (% of total)
16:0 (PA)

18.00±1.21a

16.41±2.38b

15.58±1.42b

16.32±1.33b

18:0 (SA)

16.68±1.82

15.92±1.75

17.810±1.58

17.02±1.29

35.91±2.60a

33.75±2.11b

33.90±2.19b

34.71±2.13a,b

Total SFA

Major Monounsaturated
16:1n7 (PoA)

1.41±1.15b

2.87±1.77a

1.25±0.80b

1.87±1.98a,b

18:1n9 (OA)

12.13±1.75a,b

12.18±1.54a

10.38±1.32c

10.91±1.58b,c

16.86±1.89a,b

17.79±2.12a

14.20±1.96c

15.35±3.22b,c

Total MUFA

Major n-6 Polyunsaturated
18:2 (LA)

18.13±2.20b

17.26±2.11b

20.49±2.33a

20.23±2.45a

20:4 (AA)

19.25±2.45b

20.41±2.48a,b

21.70±3.10a

20.95±2.82a,b

39.14±2.83b

39.40±3.27b

44.32±3.49a

42.70±3.29a

Total n-6

Major n-3 Polyunsaturated
18:3 (ALA)

0.20±0.08

0.19±0.10

0.22±0.09

0.22±0.07

20:5 (EPA)

0.64±0.37

0.73±0.29

0.67±0.29

0.68±0.27

22:5 (DPA)

1.53±0.43b

1.79±0.33a

1.63±0.38a,b

1.55±0.36a,b

22:6 (DHA)

5.47±1.80a,b

6.33±1.92a

4.97±1.59a,b

4.78±1.56b

Total n-3

7.87±1.94a,b

9.06±1.99a

7.53±1.63b

7.24±1.60b

Total PUFA

47.01±3.56c

48.46±3.19b,c

51.85±3.01a

49.94±3.87a,b

6.12±2.03a,b

7.06±2.11a

5.63±1.74a,b

5.46±1.71b

AA:DHA ratio

3.5

3.2

4.4

4.4

DHA:DPA

4.0

3.7

3.3

3.3

EPA+DHA

1

AA, Arachidonic acid; ALA, α-linoleic acid; DHA, Docosahexaenoic acid; DPA,

Docosapentaenoic

acid;

EPA,

Eicosapentaenoic

acid;

LA,

Linoleic

acid.

MUFA,

Monounsaturated fatty acids; OA, Oleic acid; PA, Palmitic acid; PoA, Palmitoleic acid; PUFA,
Polyunsaturated fatty acids; SA, Stearic acid; SFA, Saturated fatty acids. Results are means±SD.
a, b

and c superscripts denote significant differences between explant heart chambers, p<0.05.
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Figure 2.4. Atrium compared to ventricles for total MUFA, total SFA and total
PUFA in Explanted Failing Human Hearts.
In explanted human hearts, differences are observed when upper and lower chambers are
compared in total monounsaturated, total saturated and total polyunsaturated fatty acids.
Explanted human atrium, open columns (
) and explanted human ventricles, filled columns

Polyunsaturated Fatty Acid
Groups of Explanted Human Heart
(% of total fatty acids)

(). *means±SD are statistically different, p<0.05.
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Figure 2.5. Atrium compared to ventricles for total n-3 PUFA and total n-6 PUFA
in Explanted Failing Human Hearts.
In explanted human hearts, differences are observed when upper and lower chambers are
compared for total n-6 PUFA and then total n-3 PUFA. Explanted human atrium, open columns
(
) and explanted human ventricles, filled columns (). *means±SD are statistically different
p<0.05.
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Table 2.7. Comparison of human explanted hearts to human donor hearts in
selected membrane phospholipid fatty acids in atria and ventricles.
Human Myocardial Membrane Phospholipid Fatty Acid
Fatty Acid

2

18:2 (LA)

Heart
Chamber

Donor
N=16

Explanted
N=22

Change1

Significant
p-values

Atria

17.0±0.3

17.7±0.3

⇑

n.s.

Ventricles

21.6±1.9b

20.4±2.4a

⇓

0.0162

Atria

22.0±1.8b

19.8±2.5a

⇓

<0.0001

Ventricles

23.3±2.5b

21.3±2.9a

⇓

0.0027

Atria

40.9±2.2b

39.3±3.0a

⇓

0.0059

Ventricles

46.8±2.1b

43.5±3.4a

⇓

<0.0001

Atria

2.1±0.4b

1.7±0.4a

⇓

0.0010

Ventricles

1.8±0.4b

1.6±0.4a

⇓

0.009

Atria

5.6±0.3

5.9±0.3

⇑

n.s.

Ventricles

4.2±1.2a

4.9±1.6b

⇑

0.0464

Atria

49.5±2.9b

47.7±3.4a

⇓

0.0059

Ventricles

53.8±2.4b

50.9±3.6a

⇓

0.0001

Atria

16.1±2.1a

17.3±2.0b

⇑

0.0131

Ventricles

13.9±2.0

14.8±2.7

⇑

n.s.

20:4 (AA)

Total n-6

22:5 (DPA)

22:6 (DHA)

Total PUFA

Total MUFA

1

Results are % of total means±SD. Change: represents either greater than (⇑) or lesser (⇓)
concentrations of fatty acids in explant hearts compared to donor hearts. 2AA, arachidonic acid;
ALA, α-linoleic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA,
eicosapentaenoic acid; LA, linoleic acid. PUFA, polyunsaturated fatty acid.

a

and

b

identify

significant differences between hearts for those chambers and fatty acid with related p-values.
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Figure 2.6. Mean DHA/DPA ratios found in atrium of donor and explanted
human hearts.
Explanted atria have a significantly greater DHA/DPA ratio than is found donor heart atria

DHA/DPA Ratio
Ventricle - Human Heart

(means±SEM), p=0.0047.
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Figure 2.7. Mean DHA/DPA ratios found in ventricles of donor and explanted
human hearts.
Explanted ventricles show a significantly greater DHA/DPA ratio than donor ventricle
(means±SEM), p=0.0027.
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2.2.4. FATTY ACID CLASSES FOUND IN ATRIUM AND VENTRICLES OF
HUMAN HEART

The division of major fatty acid classes, SFA, MUFA and PUFA show similarities in
percentage of total phospholipid fatty acids between atrium and ventricles in the human
heart (Figure 2.8). The classes of n-6 and n-3 PUFA also follow a similar trend. The
individual n-6 PUFA AA and n-3 PUFA DHA show clear differences in percentage of

atri um

total phospholipid fatty acids between atria and ventricles (Figure 2.8).

PUFA Classes

FA classes

n-6 PUFA
n-3 PUFA

PUFA classes

Individual PUFA

individual PUFA

ventri cl e

SFA

MUFA

LA (18:2n-6)
AA (20:4n-6)
other n-6PUFA
EPA (20:5n-3)
DHA (22:6n-3)
other n-3PUFA

PUFA

FA classes
PUFA classes
individual PUFA
0
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100

% of total phospholipid fatty acids
Figure 2.8. Division of major fatty acid classes and PUFA in the human heart.

Graphically the division of FA (fatty acid classes) and PUFA classes within atrium and
ventricles tend towards similar trends, with individual fatty acids showing clear
differences.
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2.2.5. AGE AND THE HUMAN HEART

2.2.5.1. As Age Increases, DHA Increases in the Human Heart
There was a positive association between docosahexaenoic acid, the principle n-3
PUFA, and increasing age in all chambers of the human heart (combined donor and
explant: LA, r2=0.1123 and p=0.0199; RA, r2=0.1697 and p=0.0033; LV, r2=0.2140 and
p=0.0003; RV, r2=0.1627 and p=0.0023). There was no significant difference in slope
of the regression line between donor and explanted human hearts (Figure 2.9).
2.2.5.2. As Age Increases, EPA+DHA Increases in the Human Heart
The n-3 PUFA, EPA+DHA, had a clear positive association with increasing age in all
chambers of the human heart (LA, r2=0.1550 and p=0.0068; RA, r2=0.1725 and
p=0.0041; LV, r2=0.2305 and p=0.0003; RV, r2=0.1645 and p=0.0023). The higher
concentration of EPA+DHA was paralleled in both normal donor and failing explanted
human hearts (Figure 2.10). The major contributor to EPA+DHA at all ages was DHA.
2.2.5.3. As Age Increases, the AA:DHA Ratio Decreases in the Human Heart
The ratio of AA/DHA reduced with increasing age in all chambers of the human heart
(LA, r2=0.2343 and p=0.0007; RA, r2=0.1493 and p=0.0080; LV, r2=0.2513 and
p=0.0001; RV, r2=0.1875 and p=0.0011) and was reflected in both normal donor and
failing explanted hearts (Figure 2.11).
2.2.5.4. Age and the percentage of the Principal n-3 and n-6 PUFA
In donor hearts the n-3 PUFA, EPA and DHA (Table 2.8), were found to increase in the
membrane phospholipid fatty acids over the human lifespan (Table 2.8). A statistically
significant increase in membrane DHA in the 40’s decade (p<0.0001, R2 0.1931) from
previous 10, 20 and 30’s ages was seen. Concurrently, DPA was lower with increasing
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age (Table 2.8). The main n-6 PUFA, LA or AA, show no clear age associations, apart
from LA having a lower concentration in donor hearts during the 20’s age decade.
Arachidonic acid was statistically the least in the 30’s age decade (Table 2.8).

Figure 2.9. The association of age and human heart membrane phospholipid DHA.
In both normal donor and failing explanted hearts, DHA increases with age. Donor tissues are indicated
by open symbols (○, □) and broken regression lines. Explanted tissues are indicated by filled symbols (●,
■) and solid regression lines. Atria are represented by circles and ventricles by squares. Goodness of fit
for data indicated by r2 value and slope of regression line significance indicated by p-value. *significant
p<0.05.
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Figure 2.10. The association of age and EPA+DHA in human heart membranes.
In both normal donor and failing explanted hearts EPA+DHA increases with age. Donor atria are
indicated by open circles (○) and for donor ventricles open squares (□), with dashed regression line.
Explanted failing atria are indicated by filled circles (●) and explanted ventricles filled squares (■), with
solid regression line. Goodness of fit for data indicated by r2 value and slope of regression line
significance indicated by p-value. *significant p<0.05.
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Figure 2.11. The association of age and human heart membrane AA:DHA ratio.
A declining AA:DHA ratio is observed in humans with age; a high AA:DHA ratio is purported to relate
to a high risk of sudden cardiac death. Donor hearts are indicated by open circles for atrium (○) and open
squares for ventricles (□) with dashed regression line. Explant hearts are indicated by filled circles for
atrium (●) and filled squares for ventricles (■) with solid regression line. Goodness of fit for data
indicated by r2 value and slope of regression line significance indicated by p-value. * significant p<0.05.
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Table 2.8. Ageing in human donor hearts and the effects on the major n-3 PUFA
and n-6 PUFA membrane phospholipid fatty acids.
Age1

Fatty Acid

No clear age association
LA
n-6 PUFA
AA

20 < 60 < 10, 30, 40, 50 age groups
No clear age association
30 < all other ages*
Increases with age up to 60

EPA

n-3 PUFA

DPA

Increased significantly from 40*
Decreases with age
10 > 20 – 60*
Increases with age including 70’s

DHA
1

Increased significantly from 40**

For ease of analysis, ages are grouped into decades, except the 60 year group, which also includes >70

year old.10: 10-19 years of age; 20: 20-29 years of age; 30: 30-39 years of age; 40: 40-49 years of age;
50: 50-59 years of age; 60: 60-79 years of age. *p<0.05, **p<0.0001

2.2.6. GENDER DIFFERENCES IN THE HUMAN HEART

2.2.6.1. Donor Hearts
Seventy five percent of total donor hearts available for transplantation were from males
(Table 2.3). Total PUFA in left atrium was found to be significantly greater in male
hearts than female hearts, p=0.0406. There were trends towards significance in the right
atrium with males greater than females in total n-3 PUFA, EPA and the n-6 PUFA, AA.
In the left ventricle, total PUFA, n-3 PUFA and DPA were found to be greater in males
than females.
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2.2.6.2. Explanted (Failing) Hearts
Males were 86% of all subjects (Table 2.4). Left atrium EPA was greater in females
than male and trended towards significance.
2.2.6.3. Female Hearts
The number of female explanted hearts (n=3) (Table 2.4) were similar in number to that
of female donor hearts (n=4) (Table 2.3). In the left ventricle of donor hearts total n-6
PUFA was significantly greater than explant hearts, p=0.0043. The concentration of
EPA was higher in explanted right atrium than in donors, p=0.312.

2.3. DISCUSSION
This study has enabled a complete characterisation of the phospholipid fatty acid
composition of freshly obtained human heart across all four pumping chambers. This
has revealed some subtle differences, yet an overall consistency between the different
chambers of the human heart.

These subtle differences may in part explain the

differences in previous reports that come from different sampling sites within the heart
and different collection and preservation conditions. Past reports generally fall into one
of two groups. The first relied on tissue sampling from human cadavers (Fletcher, 1972;
Gudbjarnason, et al., 1975a; Belfrage, et al., 1979; Sexton, et al., 1995) at indeterminate
times after death and without collection and preservation procedures associated with
fresh tissue handling.

The second group were able to freshly obtain small, intra-

operative biopsy samples (Rocquelin, et al., 1985; Rocquelin, et al., 1989; Harris, et al.,
2004a; Garg, et al., 2006; Metcalf, et al., 2007; Metcalf, et al., 2010) and acutely
preserve them under optimal conditions. An assessment of the left ventricular fatty acid
composition of explanted hearts found in this study compared most favourably to the
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intra-operative left papillary muscle samples of Rocquelin et al. (1985), with similarities
in the major n-6 PUFA (LA and AA) and n-3 PUFA (ALA, EPA, DPA and DHA)
concentrations. The viable donor left ventricles analysed here are distinguished by
greater LA and AA concentrations when compared to Rocquelin et al. (1985) samples.
In turn, the intra-operative right atrial appendage samples of Garg et al. (2006) and
Metcalfe et al. (2007, 2010) are largely in concordance with data presented here for
right atrial samples. Therefore, these findings establish that intra-operative atrial or
papillary muscle samples taken under the ethical constraints of minimal biopsy size
during elective surgical procedures well-represent the true heart composition for those
heart regions as confirmed in this study using the substantial tissue samples taken under
conditions more akin to carefully controlled animal studies.
Membrane phospholipid fatty acid compositions are true for those sites sampled, with
differences well described between tissues of origin.

Data derived from right

interventricular septum biopsies (Harris, et al., 2004a) stand in contrast to any cardiac
tissue of this study or of the intra-operative atrial or papillary muscle biopsies
previously reported, having much lower PUFA concentrations (both n-3 PUFA, and n6 PUFA). Within that study, the low PUFA concentrations, including low DHA
concentrations, are much more in line with cheek cell samples than with red blood cells
or plasma phospholipid from the same subjects. The contrast to other ventricular
samples and similarity to cheek cells suggests that these very small samples taken to
assess immune function and tissue rejection may in fact be more ventricular epithelium
than myocardium. Contrasting membrane composition is well described between tissue
types within species. For example, in a non-human primate the marmoset monkey,
markedly more DHA is recorded in excitable (neural, myocardial or skeletal muscle)
tissue (Charnock, et al., 1989; Charnock, et al., 1992). In human tissue, DHA and other
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PUFA vary between tissues (Lund, et al., 1999; Baur, et al., 2000; Connor, et al., 2000;
Harris, et al., 2004a; Arterburn, et al., 2006) although the differences reported between
excitable and non-excitable tissue are not so clear cut and may be influenced by
sampling procedures, (Arterburn, et al., 2006) report heart composition from the human
intraventricular septum biopsy (Lund, et al., 1999; Harris, et al., 2004a), which this
study shows to be uncharacteristically low in DHA and other PUFA.
When using cadaveric tissue, Gudbjarnason et al., (1975, 1976, 1978), Belfrage et al.,
(1979), and Shenolikar (1980) under-reported many of the membrane phospholipid FA
compared to those found in freshly obtained cardiac muscle. Sexton et al. (1995) was
able to report a complete profile of phospholipid FA from cadaveric samples, however
as with all cadaveric samples, analyses can be affected by autolysis during the waiting
time for procurement.
Trends in cardiac membrane phospholipid FA across animal studies are difficult to
interpret. Taken in light of animal species differences (Simon, et al., 1969), the data
required for comparisons are either not documented, or are missing on analysis, due to
the differences in scientific questions and experimental methodologies; for example,
early gas chromatographic (GC) techniques often did not allow sufficient run times to
identify the very long-chain polyunsaturated fatty acids (such as DHA) or separation of
DHA from very long chain saturates. As well, the specificity of GC column technology
has greatly improved since those early reports and continues to do so. Whereas animal
heart tissue is readily obtainable, procurement of human heart tissue is problematic,
however due to human heart transplantation; this study provided a complete analysis of
the membrane phospholipid FA composition of each chamber of normal, donor and
failing, explanted human hearts. However a modest comparison of studies of unsupplemented animals found the atria and ventricles of marmoset monkeys and rat
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compared favourably to DHA concentrations found in this human study. No further
parallels can be found between animal data and the human data, apart from a reasonable
conformity between animal and human hearts for the predominant n-3 PUFA of DHA,
as well as the abundance of the n-6 PUFA, LA and AA, the SFA, PA and SA, and the
MUFA OA in cardiac membranes. As with animals, ALA is found in near undetectable
amounts, EPA is less than 1% of total and DPA remains relatively consistent.
The recent American Heart Association Science Advisory (AHA, et al., 2009) states a
diet of 5 to 10% of energy from n-6 PUFA, with an emphasis towards LA (~12 g for
women and ~17 g for men) (Harris, 2010) as reducing the risk for CHD; recommended
tissue and blood FA concentrations of LA and AA have not been given. The AHA
advisory has been used by basic scientists in papers in attempting to understand the
influence of diet on heart disease (Rennison, et al., 2009) without full disclosure of a
range of fatty acid concentrations; unlike Harris and von Schacky (Harris, et al., 2004b)
in determining acceptable ranges of red blood cell EPA+DHA concentrations for
cardioprotection, >8% of total (for the omega-3 FAs, a healthy target intake is about
500 mg per day (whether from oily fish or fish oil capsules)). Understanding that there
is competition between dietary n-6 PUFA and n-3 PUFA for the same desaturase
enzymes, delta-6 (∆6) and delta-5 (∆5), for FA chain desaturation (the rate limiting step
in carbon chain desaturation), increasing dietary n-6 PUFA will jeopardise the ability of
the available dietary n-3 PUFA to synthesise longer chain PUFA from ALA.
The donor human hearts analysed in this study were regarded as normal, “healthy”, or
viable (free of disease) and were initially intended for human heart transplantation.
Further, these hearts from the broader community (free of overt heart disease) afforded
a platform for analysis of cardiac membrane phospholipid FA compositions over the
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course of the human lifespan. On the other hand, the explanted failing hearts were taken
from a highly selected cardiac patient population, whose hearts have substantial
underlying cardiac pathology and so provide a unique comparison to normal human
cardiac membrane phospholipid FA profiles. These patients had no known clinical
dietary intervention, therefore maintained a normal habitual diet too.
Focusing on the n-3 PUFA, DHA and EPA and regardless of group, this study has
importantly demonstrated that over the course of the human lifespan, the fatty acids
DHA and EPA+DHA increase in the membranes of cardiac muscle, in all four
chambers; this is in line with an earlier observation of Gudbjarnason and Hallgrimsson
(1975, 1978) of membrane phospholipid PUFA being “a function of age (and sex)”. It
was also demonstrated that with increasing age, the AA:DHA ratio decreased,
corresponding further with Gudbjarnason and Hallgrimsson (1976). Hearts with very
high AA:DHA ratios are proposed to be at a greater a risk of sudden cardiac death
(Gudbjarnason, et al., 1976); two explanted hearts were identified with obviously high
AA:DHA ratios in the left atria, but these identified explanted hearts did not exhibit
high ratios in other chambers. An explanation for this trend can be explained from the
observations reported for the first time in this study. Such that, total PUFA was found
to be significantly less in both atria and ventricles of explanted hearts when compared to
donor hearts. This reflected significant reductions in LA, AA and total n-6 PUFA, and a
modest reduction in the n-3 PUFA, DPA. In contrast the n-3 PUFA, DHA was found to
be higher in explanted atria and ventricles, respectively. The data presented here show
the differences in membrane phospholipid FA between normal and failing human
hearts. The outstanding difference was the significantly greater concentration of DHA in
failing ventricle (non-significant trend in atria) whereas all other PUFA were found in
lower concentrations. The increase in DHA was further exemplified as a higher ratio of
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DHA: DPA in all chambers, suggesting greater rate of conversion of long-chain n-3
PUFA. The increased myocardial DHA in failing hearts may represent an adaptive
response of the cardiac muscle to the pathophysiological stress states. Animal studies
indicate that DHA is increased after exposure to pressure overload (Reibel, et al., 1986)
and during catecholamine stress (Emilsson, et al., 1983; Gudbjarnason, 1989;
Gudbjarnason, et al., 1995, 1996). Comparative physiology shows myocardial DHA
concentrations increase in association with the well-established relationship between
diminishing animal size and increasing metabolic rate and heart rate (Gudbjarnason, et
al., 1978a; Gudbjarnason, et al., 1978c). In contrast, dietary induced increase in
myocardial membrane DHA concentrations is associated with lower heart rate
(McLennan, et al., 2005), reduced catecholamine-induced arrhythmias (Gudbjarnason,
1989) and reduced hypertrophic response to pressure overload in controlled animal
studies and in man is also associated with reduced heart rate (Geelen, et al., 2005;
Mozaffarian, et al., 2005b), reduced sudden death (Marchioli, et al., 2002) and reduced
heart failure (Tavazzi, et al., 2008a). Indeed a number of stress-induced changes in
membrane DHA composition can be seen as adaptive responses since similar changes
brought about by diet are cardioprotective (McLennan, et al., 2005).
In the left side of the heart, which generates significantly greater atrial and ventricular
pressures than the right side of the heart, the principle n-3 PUFA, DHA was found to
have a more limited range in concentration than the right side of the heart in both donor
and explanted hearts. Whether there is significance in this observation remains to be
elucidated, but it is interesting to note that DHA concentrations in the right atria were
the highest of all chambers; the chamber more likely to be biopsied and used for
comparisons to red blood cell membrane phospholipid FA EPA+DHA (RBC
EPA+DHA). Also known as the Omega-3 Index (Harris, et al., 2004b), RBC
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EPA+DHA is an index which can be used as a biomarker and possibly a risk factor for
heart health in humans; RBC EPA+DHA ≥8% - superior cardioprotection, ≤4% reduced cardioprotection.
Sex differences are seen in heart membrane phospholipid FA composition and heart
function and dysfunction (Du, et al., 2006), which can be attributed to the diet (SlaterJefferies, et al., 2010), sex hormones (Du, et al., 2006; Childs, et al., 2008), liver uptake
(Luxon, et al., 1998) and the recently identified differences in human cardiac stem cells
(hCSCs) (Kajstura, et al., 2010). The study participants here were principally male in
both explant and donor hearts. The small number of female hearts in this study would
preclude definitive conclusions to be drawn between the sexes. However, close
approximations of FA concentrations in males and females was observed by Rocquelin
et al., (1985), moreover males are more likely to be affected by heart disease than premenopausal women due to the lack of any oestrogenic protection (Du, et al., 2006).
Substantially most papers conferring human heart membrane fatty acid data have
limited female participation; Garg et al., (2006) 6% were female, Metcalfe et al.,
(2007, 2010) had 10% and 20% female participants respectively, and Harris et al.,
(2004) had 25% female study participation. The mechanistic significance of DHA
increasing in cardiac tissues with age is yet to be fully elucidated, yet in aging hearts
increased DHA may well be an adaptive response (Pepe, et al., 2002) as in other cardiac
stress.

2.4. CONCLUSION
This study has provided an opportunity to establish the fatty acid composition of human
heart in freshly obtained tissue using collection, storage and analysis methods that are
the same as commonly used for animal dietary intervention studies. Previous studies
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with membrane phospholipid fatty acid analysis of the human heart have examined
tissue that was obtained from cadavers of variable and indeterminate time of death
(Fletcher, 1972; Gudbjarnason, et al., 1975a; Sexton, et al., 1995) or very small intraventricular biopsy (Harris, et al., 2004a). The study revealed that amongst the n-3
PUFA, EPA was present at very low concentrations, consistently less than 1% of the
fatty acids in any heart chamber. Docosahexaenoic acid was shown to be consistently
greater than ALA, EPA or DPA in all chambers, with AA and LA the predominant n-6
PUFA. Docosahexaenoic acid and EPA but no other PUFA, changed with age, as
shown by the reduced AA:DHA ratio. There was no difference in age between donor
and explant hearts. Comparison of chambers showed total n-3 PUFA to be greater in the
atrium than the ventricles and total n-6 PUFA to be greater in the ventricles than atrium.
The results indicate that DHA is the principle n-3 PUFA in the human (as seen in
animal) heart and that it increases with age and under stress as seen in laboratory
animals. This data provides a baseline for evaluation of human heart samples taken by
biopsy within dietary studies.
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Chapter 3

FATTY ACID COMPOSITION OF RED BLOOD CELL
MEMBRANES AS A MARKER OF HUMAN HEART
MEMBRANE PHOSPHOLIPID FATTY ACIDS
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3.0. INTRODUCTION
The n-3 PUFA are essential to the human diet, due to the inability of mammals to
synthesize these fatty acids de novo. Desaturase and elongase enzymes are capable of
altering the precursor fatty acids, EPA and alpha-linolenic acid (ALA, 18:3n-3) into the
long-chain DHA, albeit in a limited fashion (Arterburn, et al., 2006) as the disparity
between amount consumed (ALA approximately 1.2 g/day in Australia) and tissue
concentrations attest (typically < 0.5% of total fatty acids) (Burdge, et al., 2005).
There is a need therefore for preformed EPA and DHA to be consumed (Arterburn, et
al., 2006; Wang, et al., 2006; Milte, et al., 2008) and dietary guidelines from numerous
countries with low EPA and DHA consumption (NHMRC, 2003; WHO/FAO, 2004;
AHA, et al., 2006; Harris, et al., 2008a; NHFA, 2008b) recommend at least two oily
fish meals (approximately 220 g total) per week, in addition to an overall healthy diet
and lifestyle plan, to help reduce heart disease risk (WHO, 2003; AHA, et al., 2006;
AHA, et al., 2009).
Extensive human and animal studies examining the ingestion of the long-chain n-3
PUFA, eicosapentaenoic (EPA, 20:5n-3) and docosahexaenoic acids (DHA, 22:6n-3),
have identified multiple mechanisms by which these fatty acids may reduce risk of
death from heart and vascular diseases. Foremost in this research is the antiarrhythmic
effect of omega-3 PUFA, principally DHA, whose incorporation into the membranes of
heart phospholipid fatty acids directly affect cellular electrophysiology (for review see
(McLennan, 2004)). Interest is growing in the role of DHA as the forerunner for
cardiovascular (CV) health due to its abundance and its avid incorporation into heart
cell membranes, graphically shown in rats in a time- and dose-dependent manner
(Owen, et al., 2004; Slee, et al., 2010). However, as species differences for membrane
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phospholipid fatty acids clearly exist (Chapter 1, Table 1.4) (Jordan, et al., 2004), it
remains to be seen whether similar relationships between dietary fatty acids and
membrane fatty acid composition holds for the human heart.
Animal studies have provided numerous examples of dietary n-3 PUFA incorporation
into the membranes of myocardial cells (Gudbjarnason, 1975, 1980; Charnock, et al.,
1983; Charnock, et al., 1985a; Owen, et al., 2004; Slee, et al., 2010) and into other cell
types. Blood plasma, platelets, leukocytes and erythrocytes (red blood cells, RBC) have
all been used to identify dietary trends of fatty acid intakes. Plasma serves as an
indicator of acute dietary intake, whereas RBC membrane phospholipids may act as a
marker of the more consistent recent diet (Brown, et al., 1991; Cao, et al., 2006).
Notably, DHA has been identified as having a time- and dose-dependent effect on RBC
membrane FA composition in humans (Milte, et al., 2008). However, different tissues
including the heart, cerebral cortex, retina, liver and kidneys in animals (Stubbs, et al.,
1984; Saito, et al., 1998; Owen, et al., 2004) and in humans: sperm, adipose tissue,
buccal epithelial cells, spleen, rectal epithelium and skeletal muscle (Arterburn, et al.,
2006) often display large differences in membrane phospholipid fatty acid composition,
particularly in relation to DHA concentrations. Nevertheless, RBC membranes in blood
samples from people who died of sudden cardiac death (SCD) having no prior known
heart disease, were more likely to be low in DHA and EPA than healthy age-matched
controls, and in turn, a low dietary fish intake was associated with these primary cardiac
arrest victims (Siscovick, et al., 1995).
Noting a pattern in the association between RBC fatty acid composition and the primary
cardiac arrest and other heart disease outcomes, Harris and von Schacky proposed the
EPA+DHA content of RBC membranes as a new risk factor for cardiac disease, which
they termed the Omega-3 Index (Harris, et al., 2004b). However, it is unlikely that the
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RBC fatty acid composition itself or any associated RBC functional change is directly
responsible for the changes in cardiovascular risk; therefore this “Index” is thought to
act as a marker of heart fatty acid composition. The collection of blood samples is a
relatively non-invasive means of assessing recent consumption of dietary fats, whereas
heart sampling is invasive and dangerous and usually only possible if coincidental with
intrathoracic surgery, most commonly from the atrium of ailing hearts.

Yet, as

described above, considerable tissue differences exist in n-3 PUFA composition
(Arterburn, et al., 2006), and with limited reports identifying the incorporation of
dietary EPA and DHA into the membranes of human cardiomyocytes (Harris, et al.,
2004a; Garg, et al., 2006; Metcalf, et al., 2007) (Table 3.1) it is not established how
well RBC act as a marker of human heart tissue.
Thus, the aim of this study was two-fold: first to characterise and contrast the membrane
phospholipid fatty acid composition of the human atrium and RBC paired from the
same subjects and obviously exposed to the same dietary patterns; and secondly, to
examine the influence of fish oil (FO) supplementation on atrial and RBC membranes
composition, also paired from the same subjects, and contrast them to subjects
supplemented with placebo.
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Table 3.1. Comparison of the Major Membrane Phospholipid Fatty Acids1 from Human Atria and Red Blood Cells after
Fish Oil Supplementation or Control Diets.
CARDIAC
Membrane Fatty Acids
Reference
Harris, 2004*
Garg, 2006
Metcalf, 2007
Harris, 2004*
Garg, 2006
Metcalf, 2007

Diet
C
C
C
F.O.
F.O.
F.O.

n-6 PUFA
N
21
9
10
21
8
10

RED BLOOD CELL
Membrane Fatty Acids
Reference
Harris, 2004
Metcalf, 2007
Harris, 2004
Metcalf, 2007

Diet
C
C
F.O.
F.O.

LA
2
9
17
14.7
8
17
13.8

AA
9
22
20.5
8
18
17.5

n-3 PUFA
EPA
0.2
0.8
0.5
0.6
3
1.4-3

n-6 PUFA
N
10
21
10

LA
10
8.5
9
6.9

AA
EPA
17
0.4
14.2
0.7
15
1.5
14.1-11.7 1.9-3.1

DPA
0.8
2
2
0.8
2
2

DHA
1.5
6.7
4.8
2.3
8
6.8-8.5

EPA+DHA
1.7
7.4
5.3
3
11.4
8.2-11.5

Total
PUFA

Total
SFA

Total
MUFA

30

35
40

15
12.6

30.8

35
38.8

14
13.2

Total
PUFA

Total
SFA

Total
MUFA

28.9

42.5

18.6

30.4

42.8

18.5

n-3 PUFA
DPA
2.7
3
3.9
3

DHA
4.2
4.4
7.5
5.7-7.6

EPA+DHA
4.7
5.1
9
7.7-10.7

* Harris et al., 2004 cardiac samples were right intraventricular biopsy from > 3 months post-heart transplant.1 Results are a percentage of total fatty
acids.

2

Values have been averaged. C - Control, F.O. - Fish Oil, AA - arachidonic acid; LA - linoleic acid; EPA - eicosapentaenoic acid; DPA-

docosapentaenoic acid; DHA - docosahexaenoic acid; SFA - saturated fatty acids; MUFA - monounsaturated fatty acids; PUFA - polyunsaturated fatty
acids.
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3.1. METHODS
3.1.1. SAMPLES

The subjects were patients scheduled for elective on-pump cardiac surgery (valve repair
or replacement or coronary artery bypass grafting (CABG)) at the Alfred Hospital,
Melbourne between March 2005 and August 2006. Thirty four subjects were
randomised into two groups at the time of preadmission clinic; the Placebo group
consumed olive oil (3 x 1 g) capsules and the fish oil (FO) treatment group, (3 x 1 g)
capsules per day. The FO supplementation delivered 540 mg EPA + 360 mg DHA per
day. Supplementation commenced on the day of the pre-admission clinic and continued
until the day of surgery, with treatment duration ranging from 13 to 93 days (mean =
42.8 days). Baseline blood samples were provided for 23 subjects, taken at their preadmission clinic. From a total number of n=31 subjects, we obtained peri-operative
blood samples and right atrial samples were obtained from 28 subjects. Paired baseline
and peri-operative blood samples were obtained from n=11 placebo and n=10 FO
subjects and paired peri-operative blood samples and right atrial samples were obtained
from n=14 placebo and n=13 FO subjects. Red blood cells and atrial samples were
obtained, handled and treated as per institute protocols. Sample handling faults and
transport failure accounted for the discrepancies in total and matched samples. Informed
consent was obtained before participation in the study, which was approved by the
Research Ethics Committee of the Alfred Hospital and Monash University Clinical Trial
registration number NCT00906646 (www.clinicaltrials.gov).
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3.1.2. SAMPLE PREPARATION AND FATTY ACID ANALYSIS

3.1.2.1. Human Red Blood Cell Preparation
i) RBC Membranes (Ghosts)
Red blood cells were stored at -80 ℃ until analysis, when the RBC samples were
thawed on ice and maintained on ice when possible throughout procedures. At the
commencement of RBC analysis, 400 µL of packed RBC where transferred to clean and
dry 10.4 mL screw-cap transparent polycarbonate ultracentrifuge bottles (BeckmanCoulter Australia Pty Ltd, Gladesville, NSW, part number: 355603). Addition of 10
mM Tris-HCl buffer, pH 7.4, was added to RBC sample to a weight of between 16.3 –
16.5 g including bottle caps and O-rings. The capped tubes were gently inverted and left
at room temperature for 30 – 40 minutes to completely lyse cells.
The samples were then spun at 3000 g ultracentrifugation (Beckman-Coulter Optima L100, fixed-angle, titanium rotor, type 70.1 Ti, part number: 342184) in vacuum at 4 ℃
for 30 minutes. The haemoglobin tainted aqueous solution was aspirated to leave RBC
membrane pellet which was washed gently with 0.5 mL of 10 mM Tris-HCl buffer, this
was also aspirated. After the addition of 200 µL distilled water, the pellet was
resuspended using a positive displacement pipette, avoiding foam to form, and allowed
to stand for several minutes.
ii) RBC Direct Transesterification
Red blood cell membrane phospholipid fatty acids were methylated to phospholipid
fatty acid methyl esters (FAME) in preparation for gas chromatography. From the
resuspended RBC membrane ghosts for each subject, 150 µL was transferred to
individual clean 7 mL glass screw-cap test-tubes, after which 2 mL methanol: toluene
(4:1, v:v) was added.
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In a fume hood whilst vortexing, 200 µL of acetyl chloride was carefully added. Taking
care of the increase in temperature, the tubes were securely capped with temperature
resistant caps and Teflon TM tape wrapped around thread of tube. The tubes were placed
in a dry heat block for 60 minutes at 100 ℃, after which the tubes were immediately
placed in ice for rapid cooling to cease further reactions. The cold tubes and samples
were vortexed whilst 5 mL of refrigerator cold 6% K2CO3 from a bottle-top dispenser
was added. Recapping tubes and after shaking vigorously for 30 seconds, the tubes
were placed in a refrigerated benchtop centrifuge at 2000 g for 10 minutes at 0 ℃. The
separation of lipid FAMEs from the aqueous phase was achieved.

The upper lipid phase was transferred carefully into 250 µL glass inserts (catalogue
number: 24701; glass inserts, shell style 0.25 mL 5mm x 31 mm, outside diameter x
height: Sigma-Aldrich/Supelco, Bellefonte, PA) which were placed in 2 mL glass
standard opening vials (catalogue number: 27078; 2.0 mL outside diameter clear vial, 8425 thread, 12 mm in diameter, 32 mm in height, and has a 4.6 mm opening: SigmaAldrich/Supelco), and tightly capped with septa (catalogue number: 27079-U; silicone
septa, red Teflon TM-faced, 8 mm: Sigma-Aldrich/Supelco) and caps (catalogue number:
5076670; holed white polypropylene caps, 8-425 thread size: Sigma-Aldrich/Supelco).

3.1.2.2. Human Atrial Sample Preparation
Right atrial samples were stored at until ready for shipping in dry ice, stored again at 80 ℃ prior to analysis, and kept ice-cold when possible during initial processes of
analysis. Briefly, tissue samples (atrium: 20 - 50 mg wet weight) were prepared by
removing obvious fatty deposits prior to homogenisation. A modified Folch (Folch, et
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al., 1956) lipid extraction technique was employed. As detailed previously (Chapter 2,
2.2. METHODS), the samples were treated equally throughout all processes of
Phospholipid Fraction Isolation, Fatty Acid Methyl Ester (FAME) Formation, FID-Gas
Chromatography and Quantification of Fatty Acids Methyl Esters.
iii) Fatty Acid Methyl Ester Formation
Briefly, all atrial membrane phospholipid fatty acids were methylated to phospholipid
fatty acid methyl esters (FAME) in preparation for gas chromatography. The derived
lipid samples were collected into clean screw-top tubes, placed in a heat block (average
temperature of 25 ℃) and dried down under nitrogen gas to pure lipid, to which 2 mL
methanol: toluene (4:1, v/v) was added. In a fume hood, whilst vortexing, 200 µL acetyl
chloride was added, the samples where then placed in the heat block for 60 minutes at
100 ℃. At the end of 60 minutes the samples were quickly removed from the heat
block and rapidly cooled in ice, to then be centrifuged at 4000 g for 10 minutes. The
resultant lipid layer was then pipette into clean deactivated borosilica glass vials, using
250 µL glass inserts.
iv) Gas Chromatography and Quantification of Fatty Acid Methyl Esters
The fatty acid methyl esters were analysed by FID-GC (flame ionizing detector - gas
chromatography) using a Shimadzu GC-17A with AOC-20i (automated sample
injection system) with a 50 m (length) x 0.25 µm (wall coating) x 0.25 mm (internal
diameter) CP-SelectTM CB for FAME capillary column (Varian, Middleburg, The
Netherlands. Catalogue number: CP7419). Each sample run consisted of 10 to 25
samples with two FAME reference standards utilised (NuChek Prep, Elysian, MN,
USA, catalogue number: GLC 673B and Sigma-Aldrich Qualitative F.A.M.E. Mix, C4C24, Catalogue number: 18919-1AMP). A 1 µL sample was injected into the split
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system using hydrogen as the carrier gas, with a temperature ramp function
commencing at 170 ℃ and rising to 210 ℃ over 24 minutes.

3.1.3. CHEMICALS

All chemicals, solvents and laboratory consumables are of analytical grade supplied by
Crown Scientific Pty Ltd (Ebos Group Ltd., Minto, NSW), Sigma-Aldrich Corporation
(Castle Hill, NSW), Phenomenex Australia Pty Ltd (Pennant Hills, NSW), BOC Gases
Australia Ltd (North Ryde, NSW), Waters Corporation Australia (Rydalmere, NSW),
Wheaton Science Products (Wheaton Industries Inc., Millville, NJ, USA) and NuChek
Prep Inc. (Elysian, MN, USA).

3.1.4. STATISTICAL ANALYSIS

Data was analysed using Statistix (version 9, Analytical Software, Tallahassee, FL,
USA) and graphed using GraphPad Prism (version 6, GraphPad Software Inc., USA).
Data are presented as mean ± SEM. The RBC baseline v RBC peri-operative and RBC
peri-operative v right atrium was analysed within treatment groups by paired, repeated
measures ANOVA. Between treatments effects were analysed by one way ANOVA
within each sample type (baseline RBS; peri-operative RBC and atria). Linear
regression and correlation analyses were conducted on individual fatty acids between
sample types. Statistically different results were accepted with p<0.05.
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3.2. RESULTS
3.2.1. HUMAN RED BLOOD CELLS

3.2.1.1. Control
Baseline red blood cell membrane phospholipids included from all subjects were
characterised by total SFA of 42.3±1.5% (mean ± standard deviation), total MUFA of
18.8±2.0% and total PUFA of 34.6±2.0%. The important n-6 PUFA, LA and AA were
present at 7.1±0.9% and 14.5±1.3% of total fatty acids respectively, with 2.8±0.6%
22:4n-6 and total n-6 PUFA of 26.2±2.0%. The major n-3 PUFA of interest, EPA and
DHA, were present at 0.77±0.26% and 4.89±1.29% respectively, with 2.54±0.24% DPA
and total n-3 PUFA of 8.22±1.24%. The baseline sum of EPA+DHA in red blood cells
was 5.67±1.31%. All fatty acids of interest are listed in Tables 3.2 & 3.3. There were
no differences in any individual fatty acid or subgroup between the placebo or FO
supplemented subjects at baseline.
3.2.1.2. Effects of Placebo or Fish Oil Supplementation
There were no differences in any individual fatty acid percent concentration or subgroup
between the peri-operative blood sample and baseline within the placebo supplemented
subjects (Table 3.2). Subjects with FO supplementation had significantly higher
concentrations of EPA, DHA and DPA, with resultant increases in sum of EPA+DHA
and total n-3 PUFA in their peri-operative blood samples. There were corresponding
decreases in the n-6 PUFA LA, AA and 22:4n-6 with a resultant decrease in total n-6
PUFA. All of these differences were observed both between placebo and peri-operative
FO samples and within the FO group between baseline and peri-operative samples
(Table 3.3). There were no differences in individual or total SFA or MUFA or in total
PUFA with FO supplementation.
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Table 3.2. Comparison of major phospholipid fatty acids from human red blood cells and atria: Placebo.
Baseline
RBC

PLACEBO
Fatty acid1
16:0 palmitic
18:0 stearic

N=

Peri-operative
RBC

Atria

Baseline RBC
versus
Peri-operative RBC
P

Peri-operative RBC
versus
Atria
P

13
19.80 ± 0.40
14.96 ± 0.23
42.26 ± 0.44

17
19.86 ±
14.99 ±
42.80 ±

0.23
0.21
0.52

14
23.08 ±
15.83 ±
40.12 ±

2.03
0.68
1.59

(n=11)
n.s.
n.s.
n.s.

(n=14)
n.s.
n.s.
n.s.

18:1 n-9 oleic
Total MUFA

11.46 ±
18.24 ±

0.36
0.73

11.15 ±
18.23 ±

0.24
0.22

10.61 ±
15.81 ±

0.53
0.67

n.s.
n.s.

n.s.
* <0.001

18:2 n-6 (LA)
20:4 n-6 (AA)
22:4 n-6
22:5 n-6
Total n-6 PUFA

7.14
14.76
2.91
0.38
26.64

±
±
±
±
±

0.23
0.33
0.18
0.05
0.44

7.38
14.81
2.93
0.38
26.92

±
±
±
±
±

0.27
0.30
0.13
0.03
0.37

16.58
18.55
0.52
0.40
36.51

±
±
±
±
±

1.05
0.90
0.07
0.21
1.77

n.s.
n.s.
n.s.
n.s.
n.s.

* <0.0001
* <0.0001
* <0.0001
n.s
* <0.0001

18:3 n-3 (ALA)
20:5 n-3 (EPA)
22:5 n-3 (DPA)
22:6 n-3 (DHA)
EPA+DHA
Total n-3 PUFA

0.04
0.70
2.56
4.89
5.59
8.17

±
±
±
±
±
±

0.02
0.06
0.07
0.28
0.25
0.24

0.04
0.74
2.56
4.84
5.58
8.15

±
±
±
±
±
±

0.02
0.05
0.07
0.22
0.20
0.19

0.11
0.28
1.47
4.54
4.82
6.39

±
±
±
±
±
±

0.01
0.08
0.11
0.29
0.28
0.33

n.s.
n.s.
n.s.
n.s.
n.s.
n.s.

* <0.001
* <0.0001
* <0.0001
n.s.
* 0.05
* 0.002

35.00 ±

0.57

35.23 ±

0.40

43.04 ±

2.01

n.s.

* <0.0001

Total SFA

Total PUFA

Phospholipid fatty acid analysis of red blood cell (RBC) samples at baseline and peri-operatively and from atria. Peri-operative samples taken after placebo
oil supplementation. 1 % of total fatty acids (means±SEM). AA, arachidonic acid; ALA, α-linoleic acid; DHA, docosahexaenoic acid; DPA,
docosapentaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid. MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA,
saturated fatty acids.* Significantly different Baseline RBC v Peri-operative RBC paired samples: repeated measures ANOVA (n= 11) and Peri-operative
RBC to Atria paired samples: repeated measures ANOVA (n=14). n.s.: not significant (P>0.05). n.d.: not detected
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Table 3.3. Comparison of major phospholipid fatty acids from human red blood cells and atria: FO supplemented.
Baseline
RBC2

FO
Fatty acid 1
16:0 palmitic
18:0 stearic

n=

Total SFA
18:1 n-9 oleic
Total MUFA
18:2 n-6 (LA)
20:4 n-6 (AA)
22:4 n-6
22:5 n-6
Total n-6 PUFA
18:3 n-3 (ALA)
20:5 n-3 (EPA)
22:5 n-3 (DPA)
22:6 n-3 (DHA)
EPA+DHA
Total n-3 PUFA
Total PUFA

20.27
14.71
42.35
12.25
19.51
7.09
14.21
2.70
0.29
25.74
n.d
0.87
2.51
4.91
5.77
8.29
34.14

10
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

Peri-operative
RBC

0.36
0.26
0.47
0.47
0.49
0.33
0.44
0.16
0.07
0.75
0.10
0.07
0.54
0.56
0.53
0.59

14
20.10 ±
14.68 ±
42.67 ±
11.95 ±
19.14 ±
†† 6.35 ±
†† 13.18 ±
†† 2.37 ±
0.44 ±
†† 23.67 ±
0.08 ±
†† 1.57 ±
† 2.90 ±
† 5.94 ±
†† 7.50 ±
† 10.42 ±
34.17 ±

0.33
0.15
0.32
0.37
0.42
0.19
0.34
0.12
0.22
0.54
0.05
0.12
0.12
0.48
0.51
0.45
0.41

Atria

Baseline RBC
versus
Peri-operative RBC
P

Peri-operative RBC
versus
Atria
P

14
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

(n=10)
n.s.
n.s.
n.s.
n.s.
n.s.
* 0.05
* 0.006
* 0.018
n.s.
* 0.003
n.s.
* 0.0002
* 0.016
* 0.008
* 0.0004
* 0.0002
n.s.

(n=13)
n.s.
n.s.
* 0.015
n.s.
* <0.001
* <0.0001
* <0.0001
* <0.0001
n.s.
* <0.0001
n.s.
* 0.018
* <0.0001
n.s.
n.s.
* 0.020
* <0.0001

22.46
14.87
38.13
11.41
16.31
16.00
19.28
0.36
0.17
36.24
0.05
†† 0.95
1.49
† 6.03
† 6.99
† 8.52
45.09

1.50
0.41
1.43
0.26
0.60
0.76
0.78
0.05
0.13
1.14
0.05
0.19
0.15
0.50
0.67
0.77
1.71

Phospholipid fatty acid analysis of red blood cell (RBC) samples at baseline and peri-operatively and from atria. Peri-operative samples taken after
supplementation with FO. AA, arachidonic acid; ALA, α-linoleic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic
acid; LA, linoleic acid. MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids. 1 % of total fatty acids
(means±SEM). 2 Note no significant differences in RBC: baseline FO compared to Placebo. † Significantly different to corresponding Placebo samples (Table
3.2.) - ANOVA: † P < 0.05, †† P<0.005. * Significantly different Baseline RBC to Peri-operative RBC paired samples: repeated measures ANOVA (n= 10)
and Peri-operative RBC sample to Atria paired samples: repeated measures ANOVA (n=13). n.s.: not significant (P>0.05). n.d.: not detected
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3.2.2. HUMAN RIGHT ATRIA

3.2.2.1. Control
Human atrial samples from placebo supplemented subjects were characterised by total
SFA of 40.1±5.9% (mean ± standard deviation), total MUFA of 15.7±2.4% and total
PUFA of 43.0±7.5%. The important n-6 PUFA, LA and AA were present at 16.6±3.9%
and 18.6±3.4% of total fatty acids respectively, with total n-6 PUFA of 36.5±6.6%. The
major n-3 PUFA of interest, EPA and DHA, were present at 0.28±0.32% and
4.54±1.10% respectively, with total n-3 PUFA of 6.39±1.25%. The sum of EPA+DHA
in the atria was 4.82±1.06%. All fatty acids of interest are listed in Table 3.2.
3.2.2.2. Effects of Fish Oil Supplementation
Subjects with FO supplementation had significantly higher concentrations of EPA and
DHA with resultant increases in sum of EPA+DHA and total n-3 PUFA in their atrial
samples compared to placebo supplemented subjects (Table 3.3). There were no other
significant differences in individual or total SFA, MUFA or n-6 PUFA or total PUFA
between the FO and placebo supplemented atria.

3.2.3. HUMAN RED BLOOD CELL COMPARED TO HUMAN ATRIUM

Atria were characterized by higher concentrations of the n-6 PUFA LA and AA and
total n-6 PUFA (especially LA, which was more than doubled) compared to their paired
peri-operative blood samples (Tables 3.2 & 3.3). There were corresponding
significantly lower concentrations of the n-3 PUFA EPA, DPA, EPA+DHA and total n3 PUFA in the atria compared with red blood cells. Total PUFA was higher in atria, the
total MUFA was lower and there was a trend to lower SFA which was significant in FO
subjects. In the atria there was a significantly higher ratio of n-3 PUFA DHA/DPA
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(atria 3.39 ± 0.41; RBC 1.93 ± 0.12) and a lower ratio of n-6 PUFA 22:4/AA (atria
0.027 ± 0.003; RBC 0.198 ± 0.008) and AA/LA (atria 1.14 ± 0.05; RBC 2.06 ± 0.10)
(Figure 3.1. Placebo).
With FO supplementation there were additional reductions in total SFA in the atria and
DHA concentration was significantly higher than in the red blood cells with no overall
significant difference in EPA+DHA between atria and red blood cells, but otherwise the
major differences between atria and RBC were seen commonly, irrespective of
supplementation (Tables 3.2 & 3.3). The greater increase in DHA in FO atria relative to
RBC resulted in further increase in the DHA/DPA ratio, whereas the other ratios were
unchanged (Figure 3.1, FO).

Figure 3.1. Ratios of specific n-6 and n-3 PUFA within membranes of red blood
cells (RBC) and atria of Placebo and FO supplemented subjects.
The increases in n-3 PUFA and decreases in n-6 PUFA were reflected in significantly lower
ratios of (LA+AA)/(EPA+DHA) in FO atria (5.56±0.45) and RBC (2.77±0.21). * RBC
significantly different to atria

3.2.4. CHANGES TO N-3 PUFA IN HUMAN RBC AND ATRIA MEMBRANE
PHOSPHOLIPID FATTY ACIDS FROM FISH OIL TREATMENT

The differences in n-3 PUFA composition between placebo and FO supplemented
subjects were most evident as increases in EPA and DHA (Figure 3.2). In red blood
cells, there were similar increases in both EPA and DHA, whereas in atria the difference
in DHA was almost twice that of EPA. There were no changes in tissue DPA or ALA
with FO supplementation.
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Figure 3.2. Baseline and effect of FO supplementation on individual and summed
n-3 PUFA in RBC and atria: Difference between Placebo and FO.
* FO significantly different to Placebo (0% difference: FO = Placebo)

3.2.5. CORRELATIONS BETWEEN FATTY ACIDS IN RBC AND ATRIA

Paired samples from all subjects (N=26) demonstrated a significant correlation between
RBC membrane EPA+DHA and atrial membrane EPA+DHA (Figure 3.4., D)
(r2=0.4286).

Indications of weaker associations were shown for other n-3 PUFA and

combinations in paired RBC and atrial samples (Table 3.4).

Table 3.4. Associations between RBC n-3 PUFA and Atria n-3 PUFA1.
RBC
EPA
EPA
EPA
EPA
EPA+DHA
EPA+DHA
EPA+DHA
EPA+DPA+DHA
DHA
DHA
DHA
DHA
DPA
DPA
RBC
EPA
DPA
Atria
DPA

Atria
EPA
DHA
EPA+DHA
EPA+DPA+DHA
DHA
DPA
EPA+DHA
EPA+DPA+DHA
DHA
DPA
EPA+DHA
EPA+DPA+DHA
DPA
DHA
RBC
DPA
DHA
Atria
DHA

Placebo
N=13
n.s.
n.s.
n.s.
n.s.
n.s.
0.018
n.s.
n.s.
n.s.
0.019
n.s.
n.s.
n.s.
0.002

FO
N=13
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.(0.06)
n.s.
n.s.
n.s.
n.s.
n.s.

n.s.(0.07)
n.s.

n.s.
n.s.(0.052)

n.s.
n.s.(0.076)

n.s.

0.019

n.s.

r2

P for slope

0.3009
0.3196
0.3228
0.2729
0.3112
0.0127
0.4286
0.2243
0.1955
0.0220
0.3136
0.1481
0.0078
0.0063

0.005
0.003
0.003
0.007
0.003
n.s.
0.0004
0.017
0.024
n.s.
0.004
0.057
n.s.
n.s.

0.1146
0.0503
0.0220

1

Except for RBC v RBC; Atria v Atria. Linear regression analysis performed on tissue fatty
acids, Significant results (p<0.05) are shown. n.s. not significant.
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In the figure following (Figure 3.3) neither RBC EPA (A, C) alone, RBC DHA (B)
alone, nor RBC DPA (D) alone correlates as well as RBC EPA+DHA (Figure 3.4, D)
does with atrial EPA+DHA. Placebo and FO RBC EPA, and Placebo and FO RBC
DHA, have trends to positive atrial association with EPA and atrial DHA respectively.
However, there are negative trends seen for association between (i) Placebo RBC EPA
and (ii) Placebo RBC DPA (significantly negative p=0.002), and atrial DHA.

Figure 3.3. Graphs A - D show associations of RBC EPA, DHA and DPA to Atria
EPA and Atria DHA.
* statistically significant; --- linear regression line for combined Placebo and FO groups
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In the figure following (Figure 3.4) neither RBC EPA (A) alone, RBC DHA (B) alone,
nor RBC EPA+DPA v RBC DHA (C) correlates as well as RBC EPA+DHA does with
atrial EPA+DHA (Figure 3.4, D).

EPA+DHA (atria)

B.

EPA+DHA (atria)

A.

C.

D. Blood EPA+DHA and Atria EPA+DHA
Overall r = 0.4286 (* p=0.0004)
Placebo r 2= 0.1223 (p=0.24)
FO
r 2= 0.2589 (p=0.09)

EPA+DHA (atria)

DHA (atria)

12
10
8
6
4
2
0

2

4

6

8

10

12

EPA+DHA (blood)

Figure 3.4. Graphs A, B, C and D associations are shown of RBC EPA, DHA and
EPA+DHA to Atria EPA+DHA and Atria DHA.
* statistically significant; ---linear regression line for combined Placebo and FO groups
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In figure following (Figure 3.5) RBC DPA has no significant correlation with RBC
DHA (A), atrial DPA (B), nor Atrial EPA+DPA+DHA (C). The Placebo supplemented
group trends to lower DHA in RBC and Atria with greater RBC DPA. DPA has no
significant correlation with RBC EPA+DHA.

Figure 3.5. Associations of the long-chain n-3 PUFA in red blood cell and atria.
A. RBC DPA and RBC and DHA. B. RBC DPA and Atria DPA and C. RBC EPA+DPA+DHA
and Atria EPA+DPA+DHA.
* statistically significant. ---linear regression line for combined Placebo and FO
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3.2.6. THE EFFECT OF TIME ON TREATMENT ON EPA+DHA IN HUMAN
RBC AND HUMAN ATRIUM

The date of the commencement of treatment was available only for 15 subjects (FO
n=8; placebo n=7).

In blood samples (Figure 3.6, A-C), plotting days of treatment

against the fatty acid concentration demonstrated the elevation of RBC EPA above
baseline and above placebo, within approximately 15 days and was sustained thereafter.
This was not so clearly identifiable in EPA+DHA or total n-3 PUFA because of the
relatively lesser change in the major n-3 PUFA DHA with FO supplementation.
In atria (Figure 3.7, A-C), DHA appeared to be elevated above placebo treated
concentrations only after 28 days of FO supplementation and this was similarly evident
in plots of EPA+DHA and total n-3 PUFA. Similarly, the smaller increases in EPA
were not evident before 28 days in atrial samples.
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Figure 3.6. Dietary supplementation effect on RBC membrane polyunsaturated
fatty acids over time.
A. Blood values of EPA maintain a higher concentration in FO subjects from approximately 15
days. B. RBC EPA+DHA is higher than placebo treated RBC after 28 days. C. Total RBC n-3
PUFA results are shifted ~2% upwards, generally by DPA.
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Figure 3.7. Fish oil dietary supplementation effect on atrial membrane
polyunsaturated fatty acids over time.
A. Atria DHA nonlinear curve fit for FO, with linear fit for Placebo. B. Atria EPA+DHA
nonlinear curve fit for FO. C. Atria n-3 PUFA nonlinear curve fit for FO.
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3.3. DISCUSSION
The Omega-3 index (RBC EPA+DHA) has been proposed as a marker of cardiac risk
(Harris, et al., 2004a; Harris, 2009). Its use is based on the premise that the membrane
fatty acid composition of red blood cells should represent cardiac n-3 PUFA content but
can be more readily sampled. In turn, many of the cardiovascular protective effects of
fish oil are likely related to physiological consequences of the incorporation of n-3
PUFA into cardiac tissue. This study showed that despite variations in concentrations
of different PUFA in red blood cell membranes compared with atrial membranes and
despite variations in PUFA responses to supplementation with fish oil, EPA+DHA in
red blood cells provides the best representation of n-3 PUFA incorporation into atrial
membranes.
The long term stability and reliability of red blood cell membrane fatty acid
composition in unsupplemented subjects was demonstrated in two ways: first, as the
absence of significant differences in any fatty acid concentration between the baseline
samples of the placebo and FO treatment groups, and secondly as the absence of
significant differences in any fatty acid between the baseline and peri-operative blood
samples within the placebo group. On this basis we can be confident that any
differences in fatty acid composition between the peri-operative blood sample and
baseline in the FO treatment group are indeed due to the fish oil supplementation.
The composition of red blood cell samples from unsupplemented subjects was
remarkably consistent with other published values from cardiac surgery candidates
(Harris, et al., 2004a; Garg, et al., 2006; Metcalf, et al., 2007). Saturated fatty acids
made up 42% of the total, MUFA made up 18% of total and n-6 PUFA made up the
majority of total PUFA. Arachidonic acid was in the greatest concentration for any
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single PUFA and at 15% was about double the concentration of the main dietary
essential fatty acid, LA (see Table 3.1). Amongst the n-3 PUFA, the main contributor
was DHA, and there was similar consistency amongst published data with DHA present
at almost double the concentration of its 22 carbon precursor DPA. The concentration
of the 20 carbon EPA was lowest of the long chain n-3 PUFA, and ALA, the shorter
plant sourced n-3 PUFA, was barely detectable.

Metcalf and co-workers recently

published a larger sample study (Metcalf, et al., 2010), which is again consistent with
the present results and previous publications. The consistency between this study and
other studies reporting red blood cell fatty acids amongst cardiac surgery candidates
within different regions of Australia (Metcalf, et al., 2007; Metcalf, et al., 2010) is
particularly high and they contrast to the north American study of Harris (Harris, et al.,
2004a), which reported higher concentrations of n-6 PUFA LA (10% c.f. 7-8.5%) and
AA (17% c.f. 14-14.5%) and lower omega-3 index (4.7% c.f. 5.1-6.3%). This may well
represent differences in the usual dietary intakes of n-6 and n-3 PUFA between these
populations.
Although fatty acid composition of individual tissues is highly reproducible and
consistent from subject to subject, especially in animal studies with controlled diets, this
contrasts with the variations in fatty acid composition according to tissue type seen both
within animal species (Charnock, et al., 1989; Bourre, et al., 1997) and amongst human
tissues (Arterburn, et al., 2006). In the current study, the atrial samples contained
greater concentrations of n-6 PUFA than were recorded in red blood cells, especially of
LA, which was more than doubled and at 17% of total fatty acids was comparable to the
AA concentration in atria. In contrast, the n-3 PUFA total and EPA+DHA were
significantly lower than in the red blood cells, by virtue of significantly lower atrial
EPA and DPA concentrations. These basic characteristics of atrial fatty acid
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composition were in line with those previously published (Garg, et al., 2006; Metcalf, et
al., 2007; Metcalf, et al., 2010) as were the key differences in n-6 and n-3 PUFA
between atrial and red blood cell membrane fatty acid composition (Metcalf, et al.,
2007; Metcalf, et al., 2010). The FO supplementation produced increases in EPA and
DHA but not in DPA, which remained unchanged, as reported previously (Garg, et al.,
2006; Metcalf, et al., 2007). The largest changes in this and other studies were seen
with the increase in atrial DHA (Garg, et al., 2006; Metcalf, et al., 2007), despite vastly
different supplementation rates and use of high EPA fish oils in previous studies.
With obvious inter-tissue differences consistently reported, the question to answer is:
What is the best marker in red blood cell membrane to represent the n-3 PUFA
composition of the heart? Does the Omega-3 index (using RBC EPA+DHA) provide
the best marker of the composition of the human atrium? Whilst both EPA and DHA
concentrations in blood cells correlated with their individual concentrations in atria, the
stronger correlation and significant slope was seen in the correlation of EPA+DHA in
blood and atria. Nothing was gained by evaluating individual n-3 PUFA nor did
inclusion of DPA contribute either as a marker in the blood or as a marker of n-3 PUFA
in the atria. In fact it impacted negatively in every consideration, with no correlation in
DPA concentration between blood and atria (r2 = 0.008) and poor correlation of
EPA+DPA+DHA between blood and atria. This is reflected in the failure of fish oil
supplementation to modify atrial DPA concentrations (Garg, et al., 2006; Metcalf, et al.,
2007) despite some increase in the red blood cells.
The n-3 PUFA, DPA (22:5 n-3) is an intermediate in the metabolism of n-3 PUFA from
EPA to DHA. Whilst not commonly recorded as a component of fish oil supplements,
DPA can be found in food sources such as red meat, and it has been proposed that this
could be the main dietary source for many Australians and an alternative dietary source
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of n-3 PUFA in those unwilling or unable to eat seafood (Howe, et al., 2007). This then
might suggest a potential role for DPA incorporation into cellular membranes as a
marker of dietary intake or n-3 PUFA status. Indeed, although DPA was present in
human red blood cells at almost half the DHA concentration, it reached 3-5 times the
concentration of EPA, as previously reported (Harris, et al., 2004a; Metcalf, et al.,
2007) and most recently (Metcalf, et al., 2010). However, the concentration of DPA in
red blood cells correlated very poorly with DPA in the atria or any other measure of n-3
status in the atria. In fact, red blood cell DPA had a significant negative correlation
with red blood cell DHA and an even stronger negative correlation with atrial DHA in
placebo subjects, which at r2 = 0.59 (p=0.002) provided the best correlation of any
found in this study. Notably, blood cell EPA was also negatively correlated with atrial
DHA in placebo treated subjects. This suggests that in unsupplemented subjects there is
some conversion of EPA and DPA to DHA or the turnover of previously acquired DHA
is much slower. In their comprehensive assessment of 61 subjects Metcalf and coworkers (Metcalf, et al., 2010) did not report these correlations, however their data
shows that the correlations of red blood cell EPA and DPA with their respective atrial
concentrations are less than unitary, indicating lower incorporation of EPA and DPA
into atria than in red blood cells. This contrasts to DHA which is incorporated into atria
at similar or greater concentrations, as was observed in the present study.

When

subjects were supplemented with fish oil, either high in DHA (this study and (Leong, et
al., 2010)) or high in both EPA and DHA (Garg, et al., 2006; Metcalf, et al., 2007) or
higher in EPA (Harris, et al., 2004a) there was very little or no change in DPA
concentrations in blood or atria, in contrast to the changes in EPA and DHA.
Amongst these observations of variation in fatty acid concentrations and correlations,
and despite some negative associations, the consistent finding of this study was that
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EPA+DHA in red blood cell membranes is the best surrogate for n-3 PUFA status in
atrial tissue, that holds up across the wide range of blood concentrations, whether
subjects are naïve to fish oil or supplemented, confirming the recent report of Metcalf
(Metcalf, et al., 2010).
This study confirmed in human tissue as previously demonstrated in animals, that DHA
is the principle n-3 PUFA in the membrane phospholipid fatty acids of both
myocardium and RBC. Preferential incorporation of DHA into heart chamber
membranes in rats is demonstrated by time- and dose-responses to FO supplementation
(Owen, et al., 2004; McLennan, et al., 2007; Slee, et al., 2010). This occurs regardless
of a high background of n-6 PUFA in the diet (Slee, et al., 2010), making it more
relevant to Western human diets and gives validity to the results seen here. Recently,
Metcalf (2010) was able to show that free-living individuals, who self-reported greater
than two fish meals per week and some amount of FO supplementation (no high doses),
had positive responses in DHA in the atrium and RBC membranes (see Table 3.1). It
has also been shown that larger FO supplements, such as 4.4 g/day (Garg, et al., 2006)
or 6 g/day (Metcalf, et al., 2007) will give larger increases in atrium membrane DHA
and EPA over time. Further, in a random subset of Framingham Offspring subjects
Harris (2012) was able to demonstrate an approximate 2% increase in RBC EPA+DHA
from FO supplementation regardless of baseline RBC EPA+DHA (Harris, et al., 2012).
We are now able to more confidently transfer trends and conclusions from rodent data
(myocardial membrane phospholipid fatty acids) to that of the human trends in
myocardial membrane phospholipid fatty acid analyses. However, it can be argued of
subjects with less than 42 days of FO supplementation, as seen in Garg (Garg, et al.,
2006), maximal incorporation of DHA into myocardial membranes has not been
achieved and a limitation for analysis.
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Herein, elective surgery for heart disease delivered a sizeable specimen of myocardial
tissue to confirm an effect of oral FO supplementation on myocardial membrane
phospholipid fatty acids. Earlier published membrane phospholipid fatty acid analyses
of the human heart have presented data from cadaveric samples (Gudbjarnason, et al.,
1975a; Heckers, et al., 1977; Gudbjarnason, et al., 1978c; Belfrage, et al., 1979; Ray, et
al., 1979; Sen, et al., 1981; Sexton, et al., 1995). Quasi-healthy intra-operative cardiac
surgery samples have been obtained from various cardiac sites; including the atria
(unknown side) (Garg, et al., 2006), right-sided interventricular septum (Harris, et al.,
2004a), right atrial appendage (Metcalf, et al., 2007), left ventricular myocardium as
papillary muscle (Rocquelin, et al., 1985) and endomyocardial biopsy (septal-apical
region of right ventricle) (Belfrage, et al., 1979). Animal studies however have marked
differences in membrane FA composition from various sites within the heart (Charnock,
et al., 1983) and regional differences may account for some variation found in the
reported values of phospholipid fatty acids found here and of those reports mentioned.
Harris (2004) provided an early insight into the incorporation of omega-3 PUFA into
human heart membranes in response to fish oil supplementation, unfortunately
extremely low DHA concentrations and PUFA in general were reported, and on the
basis of the current study and others must remain contentious, reflecting the possibility
for the biopsy sample to be epithelium and not myocardium (Harris, et al., 2004a).
The amount of myocardial tissue disruption in cardiac surgery for valve
repair/replacement is very different to surgery for coronary artery bypass grafting
(CABG), where CABG surgery can be portrayed intrinsically as vascular surgery.
Damaged heart tissue or ischaemia, is determined by blood serum assay levels of
troponin I (cTnI) (Adams, et al., 1993); progressive ischaemia results in higher cTnI
levels. Leong (2010) recently reported a reduction in cTnI levels in both CABG
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(significantly) and valve surgery (non-significantly) after the inclusion of oral FO
supplementation (3 g/day), as part of an oral metabolic therapy prior to surgery (Leong,
et al., 2010). Animal studies show post-ischaemic oxygen utilisation, cardiac output and
external work are all improved after FO feeding (Pepe, et al., 2002; McLennan, et al.,
2007; Pepe, et al., 2007). Furthermore, FO incorporation limits myocardial infarct size,
inhibits post-ischaemic arrhythmias and improves contractile recovery in ischaemiareperfusion (Abdukeyum, et al., 2008).
The delta-6 desaturase enzyme is the rate-limiting step in the bio-synthesis of the n-3
and n-6 PUFA long chain fatty acids, AA, EPA and DHA (Horrobin, 1993) (Chapter 1,
Figure 1.1). With competition between substrate LA and ALA, precursor/product
desaturation is reportedly preferentially directed in favour of n-3 PUFA (Brenner, 1974;
Holman, 1986). However, dietary consumption is weighted more towards n-6 PUFA
intakes, particularly LA (AHA, et al., 2009), and conversion of ALA to EPA and DHA
is limited in humans (Burdge, et al., 2005; Arterburn, et al., 2006). It is generally
agreed that to overcome this imbalance, dietary consumption of preformed long chain
fatty acids AA (from meat, eggs and some fish), EPA and particularly DHA (from fish
or FO) is required. Investigation of n-6 and n-3 PUFA product/substrate ratios (Figure
3.1) in this study demonstrated the common trend in red blood cell membrane and
myocardial membrane phospholipid fatty acids, and in the face of FO supplementation.
Compared to atria, red blood cell membranes showed higher ratios of arachidonic
(20:4n-6) to linoleic acid (18:2n-6) (AA/LA) and 22:4n-6 to arachidonic acid (22:4/AA)
within the n-6 PUFA, and they remained relatively constant between placebo and FO
supplemented subjects. The atria also had higher ratios of the n-3 PUFA,
docosahexaenoic (22:6n-3) to docosapentaenoic acid (22:5n-3) (DHA/DPA), which was
further increased with FO supplementation.
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Cardiac surgery patients are at a greater risk for post-operative cardiac arrhythmias,
such as atrial fibrillation (AF) after CABG and valve repair (Ommen, et al., 1997).
Several human trials have shown AF to be reduced post-operatively after FO
supplementation (Calò, et al., 2005; Leong, et al., 2010); Leong used fish oil in
conjunction with other oral metabolic supplements which reduces certainty that the
observed effects can be specifically attributed to the fish oil, moreover three randomised
controlled trials (Saravanan, et al., 2009; Heidarsdottir, et al., 2010; Farquharson, et al.,
2011) have recently found no effect on AF. This is an intriguing area of requiring
further research. Also, fish consumption as tuna and baked or broiled fish from one to
greater than five serves each week was associated with a 28% to 31% reduction in risk
of AF in the elderly (Mozaffarian, et al., 2004). Initially evidence from animal studies
demonstrated the strong influence of reduced ventricular arrhythmias following a diet
which included FO (McLennan, et al., 1988; McLennan, 2001), especially in cross-over
diets of saturated fat to FO (McLennan, et al., 1990; Pepe, et al., 2007). However in
contrast to ventricular arrhythmias, no animal models exist that can demonstrated
experientially the efficacy in preventing AF and clinically, some contention still
remains regarding the cardiac benefits of FO and the incidence of AF from
observational studies (London, et al., 2007) and one large prospective trial (Kowey, et
al., 2010) in non-surgical patients. When fish oil supplements are initiated only at presurgical check, which is usually planned no more than 2 weeks later, the effectiveness
of the intervention, requiring incorporation into membranes of the atria may also be
obscured by insufficient time for adequate incorporation.
Based on the basic effects of n-3 PUFA EPA on eicosanoid metabolism and platelet
aggregation, there has been a long-held concern that pre-treating patients with fish oil
could put them at risk of bleeding events. This is particularly important in
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cardiovascular disease patients who may need surgery to correct valves or coronary
vascular stenosis. Blood loss is a major concern for any cardiac surgery, peri- or postoperatively and there is some evidence to suggest an increased risk of adverse outcome
after RBC transfusions (Murphy, et al., 2007). However, length of stays in hospital for
surgical procedures vary widely and peri-operative measures with supplementation of
omega-3 fatty acids can be seen to assist patients in reducing hospital stays by 1 - 2 days
and thus, hospital costs (Leong, et al., 2010).

Importantly, a period of high FO

supplementation prior to cardiac surgery was shown not to increase specifically
measured blood loss peri- or post-operatively (Metcalf, et al., 2007).
There have been volumes written on various mechanisms displaying attributes towards
the initiation and progression of heart disease in animals and humans. Alternatively,
under the influence of the omega-3 PUFA some mechanisms can inhibit heart disease
progression (McLennan, et al., 1996; Stillwell, et al., 2003) with effects on
inflammation, thrombus formation, vascular endothelium, smooth muscle cells, blood
triacylglycerides and cell membrane components (Adkins, et al., 2010) and intracellular
enzymes and cell signalling (Siddiqui, et al., 2008).
This study chapter was able to demonstrate the utility of the Omega-3 Index using data
derived from red blood cell membrane and human atrium membrane phospholipid fatty
acids taken from the same human individuals. Notwithstanding variations demonstrated
in PUFA concentrations of red blood cell and atrium samples and regardless of
variations seen in PUFA responses after fish oil supplementation, EPA+DHA in red
blood cells is shown to be the best demonstration of n-3 PUFA incorporation into atrial
membranes.
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3.4. CONCLUSION
This study clearly shows that the composition of membrane phospholipid fatty acids of
human atria can be changed through dietary means by the consumption of omega-3 fatty
acids as FO. We can only show this incorporation if we have baseline blood samples
and post-supplementation blood samples. The response would be the same for atrial
samples also, if the technique of heart biopsy was neither invasive nor dangerous.
These results clearly demonstrate the Omega-3 Index positively indicating a correlation
to human atrium EPA+DHA content. From this study the ‘Omega-3 Index’ can be used
as a marker of right atrial membrane EPA+DHA established by direct comparison of
human atrial membrane and RBC membrane samples.
Differences in membrane fatty acid compositions of different tissues in humans as
shown here reflect those of compositional differences seen in animals, especially in the
heart and red blood cell membranes and as such, support the role for continuing animal
studies in the area of dietary modification and membrane analyses.
This study established that DHA is the main n-3 PUFA in human heart and atrial
biopsy.
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Chapter 4

OMEGA-3 FATTY ACIDS IN THE HUMAN
HEART: CORRELATION BETWEEN ATRIA,
VENTRICLE AND ERYTHROCYTES

Discussion and Final Conclusions
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4.0. INTRODUCTION
Omega-3 polyunsaturated fatty acids (n-3 PUFA) are cardioprotective in man and in
animals.

Controlled animal studies indicate that, independently of effects on

vasculature, platelets and blood lipids, which may influence blood pressure,
atherosclerosis and other inflammatory processes, many cardioprotective effects are
associated with the incorporation of the n-3PUFA into myocardial membranes. The
percentage of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA) in the
human red blood cell (RBC) (termed the Omega-3 Index) correlates inversely with
adverse cardiovascular outcomes and is proposed as a cardiovascular risk factor (Harris
& von Schacky, 2004). There are no known influences on red blood cell properties that
could directly contribute to this reduced risk. Therefore the association is made on the
premise that RBC membrane is a marker for n-3 PUFA availability for action or
incorporation at an alternative site, specifically the heart and therefore reflects the
composition of myocardium EPA+DHA concentrations. In particular it should reflect
the incorporation into ventricular myocardium if it is to indicate the risk of fatal
ventricular arrhythmias, myocardial dysfunction or heart failure.
Patterns of incorporation of DHA, as the predominant n-3 PUFA in membrane
phospholipid fatty acids (Arterburn, et al., 2006), and other fatty acids, vary across
different tissue types, such as the heart, brain and RBC, in humans (Arterburn, et al.,
2006), just as they do in animals. This was confirmed in Chapter 3, where
compositional differences between atria and RBC were observed within subjects when
sampled at the same time, with or without fish oil supplementation, that were not seen
between subjects in RBC samples taken at different times, unless subject to fish oil
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intervention. Clearly the compositional differences between atria and RBC are real
differences, not due to sampling error or inter-subject variability.

Myocardial samples for membrane phospholipid fatty acid analysis are usually taken
opportunistically from living humans during cardiac surgery or in routine post-operative
heart transplant checks. The quality of some human atrial or ventricular biopsy
sampling can be questioned, as for example, previous reports have shown lower than
expected DHA and EPA concentrations in fresh ventricle samples when compared to
other studies from cadaveric or fresh peri-surgical sampling (Chapter 3, Table 3.1).
With respect to n-3 PUFA in the present study EPA and DPA concentrations in atria
were significantly lower than RBC, but no difference was seen in DHA. Nevertheless,
these membrane phospholipid fatty acids in the heart (EPA+DHA) showed the best
correlation with the more readily obtained RBC membrane phospholipid EPA+DHA
(Chapter 3, Table 3.4) for Omega-3 Index assessment.
It was unclear however if the above measures could be reflective of membrane
phospholipid EPA+DHA of the left ventricle (as the prime functional focus of cardiac
risk). It was the purpose of this thesis to set a baseline for human ventricular fatty acid
composition and establish the relationship between EPA+DHA in human RBC, atria
and ventricles.

4.1. EPA AND DHA IN HUMAN RED BLOOD CELLS AND THE
HUMAN HEART
This thesis has established that docosahexaenoic acid is the major n-3 PUFA in
membrane phospholipid fatty acid in human heart (both atria and ventricle) and in RBC.
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This preferential incorporation of DHA over EPA was further emphasised when FO
supplementation (Chapter 3) provided EPA > DHA but DHA concentration increased
more than EPA concentration did in both RBC and atria. Although significant
differences between donor right atria DHA and donor left ventricle DHA were
identified (Chapter 2, Table 2.3), EPA concentration was less than 1% of the total fatty
acids in these tissues and no significant differences in EPA concentrations were
identified between the tissues. The increase in DHA concentration after FO
supplementation was also greater in atria than in RBC and the concentration range
(particularly upper limits) in heart tissue (especially atria) was greater than in RBC;
DHA ranges: right atria biopsy of 3.2 - 7.6 % (% total fatty acids), donor right atria of
2.9 - 10.8 %, donor left ventricle of 2.5 - 6.6% and red blood cells DHA of 3.5 - 6.3 %
(means±SD are shown in Chapter 2 and Chapter 3, Figure 3.2 & 3.3). This variability
in control (unsupplemented) samples suggests that the myocardial DHA concentration
may be highly susceptible to dietary availability (provision or deficiency).

4.1. Table-1. Important n-3 PUFA content of several human tissue types without
fish oil supplementation.
EPA

*DHA

^EPA+DHA

RBC (n=13)

0.69±0.23

ab

5.11±0.78

ab

5.65±0.77

Right Atria Biopsy (n=14)

0.28±0.09

ab

4.54±1.12

ab

4.82±1.10

Donor Right Atria (n=16)

0.74±0.30

a

6.12±2.1

a

6.86±2.33

Donor Left Ventricle (n=16)

0.75±0.39

4.42±1.23

b

5.17±1.56

b

Results are mean±SD% of total fatty acids; *DHA - a General ANOVA identified significant
differences in tissues, p=0.0217 with Tukey HSD multiple comparisons, p<0.05, identifying
a
Right Atria Donor significantly different to bLeft Ventricle Donor; ^EPA+DHA - a General
ANOVA identified a trend towards a significant differences in tissues, p=0.0608 with Tukey
HSD multiple comparisons, p< 0.05, identifying Donor Right Atria as significantly different to
Donor Left Ventricle.

99

Neither mean DHA nor mean EPA+DHA concentration in RBC was significantly
different to mean myocardial concentrations in atria or ventricle in the absence of fish
oil supplementation (Table 4.1).

4.2. TISSUE
SUBJECTS

FATTY

ACID

CORRELATIONS

IN

HUMAN

The Omega-3 Index (red blood cell EPA+DHA concentration), correlated within human
subjects to their matched right atrial membrane phospholipid EPA+DHA concentration
(p=0.0004) (Figure 3.4); with a close to unitary correspondence to concentrations
between the two tissues. A similar finding was shown by Metcalf (Metcalf, et al., 2010)
from a larger sample size. Moreover, Metcalf (Metcalf, et al., 2010) and the present
study both concur in showing a unitary correspondence between RBC and right atrial
DHA yet a less than unitary correspondence between RBC EPA and right atrial EPA
(RBC EPA > right atrial EPA).
The missing link in confirming the direct association between the RBC Omega-3 Index
to cardiac risk is its correspondence to ventricular tissue concentration. Ventricular
muscle samples are rarely obtained under ideal conditions (e.g. cadaveric samples, see
Chapter 2). Those that have been obtained as intraventricular biopsy, despite their
correlation with RBC omega-3 index and dose response to fish oil supplementation
(Harris, et al., 2004a) (Table 1.1) most likely represent the composition of ventricular
endothelium, being so very different in composition to either fresh ventricular samples
of this and other studies (papillary biopsy: (Rocquelin, et al., 1985) or cadaveric
ventricular samples (Gudbjarnason, et al., 1978b; Belfrage, et al., 1979; Sexton, et al.,
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1995); low in both n-6 PUFA and n-3 PUFA and more in line with composition of
human buccal epithelial (cheek) cells (Arterburn, et al., 2006).
Matched samples from human donor right atria and donor left atria were strongly
correlated in membrane phospholipid EPA+DHA concentrations in donor subjects
(Figure 4.1). As with the correlations between RBC and right atrium, the relationship
while strongly correlated, was not unitary, with higher concentrations of EPA+DHA in
right atria than in left atria.

Human Left Atrium
(EPA+DHA % of area total)

15

r2=0.7870
12
9
6
3
0
0

3

6

9

12

15

Human Right Atrium
(EPA+DHA % of area total)

Figure 4.1. Membrane EPA+DHA in donor right atrial samples and donor left
atrial samples from heart transplant programme.

Linear regression line with 95% CI (confidence interval) for right atrium EPA+DHA
goodness of fit to left atrium EPA+DHA (n=20), r2 = 0.7870. The slope is significantly
non-zero p<0.0001. Data from Chapter 2
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Matched samples from human donor left atria and donor left ventricles were also
strongly correlated in membrane phospholipid EPA+DHA concentrations in donor
subjects (r2=0.8, non-zero slope significance p<0.0001, n=20) (Figure 4.2) but unlike
the left and right atria showed one: one or unitary correspondence between the tissues.

Human Left Ventricle
(EPA+DHA % of area total)

15

r2=0.8062
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Human Left Atrium
(EPA+DHA % of area total)

15

Figure 4.2. Membrane EPA+DHA content of human left atrium and left ventricle
in donor hearts from transplant programme.

Linear regression line with 95% CI (confidence interval) for red blood cell EPA+DHA
goodness of fit to right atrium EPA+DHA (n=20), r2 = 0.8062. The slope is significantly
non-zero p<0.0001. Data from Chapter 2

Matched samples from human donor right atria and donor left ventricles were strongly
correlated in membrane phospholipid EPA+DHA concentrations in donor subjects
(r2=0.7, non-zero slope significance p<0.0001, n=20) (Figure 4.3) and like the left and
102

right atria showed non-unitary correspondence between tissues, with right atrial
concentrations higher than corresponding left ventricle.

Human Left Ventricle
(EPA+DHA % of total area)
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Figure 4.3. Membrane EPA+DHA in human right atrium and left ventricles in
donor.

Linear regression line with 95% CI (confidence interval) for red blood cell EPA+DHA
goodness of fit to right atrium EPA+DHA (n=20), r2 = 0.7328. The slope is significantly
non-zero p<0.0001. Data from Chapter 2

4.3. DISCUSSION
Medical science has shown that n-3 PUFA are cardioprotective in numerous animal
models such as dogs (Billman, et al., 1994; Billman, et al., 1999), cats (Reibel, et al.,
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1986), rats (McLennan, 2001; McLennan, et al., 1988; Pepe & McLennan, 1996, 2002),
rabbits (Murnaghan, 1981; Den Ruijter, et al., 2012) and mice (Huggins, et al., 2009).
Docosahexaenoic acid has been identified as the principal n-3 PUFA in rat myocardium
(Gudbjarnason, et al., 1975a; Charnock, et al., 1983) and in other animals such as the
non-human primate, marmoset monkey (Charnock, et al., 1985a), mouse (Huggins, et
al., 2009), cat (Reibel, et al., 1986) and dog (Billman, et al., 2011) and it is the
purported active constituent of fish oil in animal studies (McLennan et al. 1996).
However, the often extremely high myocardial concentrations of DHA in many animals,
particularly in small rodents after fish oil supplementation, raises a question over the
relevance of animal studies to the human. Nevertheless, this thesis, through a series of
analyses using human RBC, atrial biopsy and transplant donor hearts has confidently
established that DHA is the major human heart n-3 PUFA and that the Omega-3 Index
(Harris, et al., 2004b) can be used as a valid marker of human heart EPA+DHA
composition. Moreover, the range of human heart DHA concentrations overlaps with
unsupplemented rat heart concentrations and follows on from the demonstration that
only small supplemental intakes in the rat, equivalent to achievable human dietary
intakes are required to modulate the rat myocardium (Slee, et al., 2010). For the first
time, individual chambers of the human heart have been evaluated to highlight the
strong correlations between myocardium EPA+DHA right atrium and left atrium, left
atrium and left ventricle, and right atrium versus left ventricle. These correlations all
point towards the validity of the RBC derived Omega-3 Index as a marker for
EPA+DHA content of the human heart.
The Omega-3 Index has been identified by several studies to give close associations
between RBC EPA+DHA and myocardial membrane EPA+DHA (Harris, et al., 2004a;
Metcalf, et al., 2007; Metcalf, et al., 2010), the analyses here show that myocardial
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membrane EPA+DHA is also strongly correlated between various chambers of the
heart. Harris makes a strong case for a low Omega-3 Index to be considered as a risk
factor for cardiovascular disease (Harris, 2007) along with high cholesterol,
hypertension, obesity and diabetes This marker can be used as a relatively non-invasive
tool, and could be utilized along with current diagnostic tools by clinicians in
determining appropriate preventative strategies for the support of heart health in our
communities, where coronary heart disease was the leading cause of death in 2007 in
Australia (NHFA, 2006; AIHW, 2010); future healthcare expenditure is projected to
cost more than $1 billion per annum in Australia due to heart failure and an ageing
population alone (Clark, et al., 2004).

As demonstrated in this thesis, the stress of advancing age in humans (see Chapter 2)
corresponded to higher DHA concentrations in myocardial membranes of donor and
explanted failing hearts increasing DHA concentrations in the heart also correspond to
the stress of cardiac failure. Similarly, myocardial DHA is seen to increase under stress
conditions in animals (Gudbjarnason, et al., 1975b) as well as in animals with faster
heart rates and higher metabolic rates (Gudbjarnason, et al., 1978c; Pepe, et al., 2002).
It even increases in the rat in association with saturated fat feeding (relative to a control
or n-6 PUFA diet (Charnock, et al., 1985b; Pepe, et al., 1996) and its associated
increases in heart rate and oxygen consumption (Pepe, et al., 2002, 2007). Myocardial
DHA is also increased by dietary supplementation with fish oil in both animals
(Gudbjarnason, et al., 1977; Charnock, 1985; Abeywardena, et al., 1987) and in man
(Harris, et al., 2004a; Metcalf, et al., 2007) and as observed in this thesis. These make
contrasting observations, with myocardial DHA being elevated in response to stress or
in animals with high heart rates and metabolic rates, yet dietary incorporation of n-3
PUFA in man and animals being associated with reduced heart rate and oxygen
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consumption, and improved myocardial function and associated cardiovascular risk
outcomes. Therefore, this thesis supports the premise that stress induced increases in
DHA are somehow physiologically adaptive (McLennan, et al., 2005) rather than
causative of cardiac dysfunction. There are no previous studies of membrane
phospholipid fatty acids from viable, healthy left ventricular muscle in humans (see
Chapter 2), except post-transplant biopsy samples from the right interventricular septum
(Harris, et al., 2004a). Interestingly, the reports of the DHA concentrations found within
the left papillary muscle in chronic rheumatic heart disease (Rocquelin, et al., 1985) are
comparable to those found here.
It is commonly acknowledged that the diet influences the composition of cell membrane
phospholipid fatty acids in most tissues in humans (Arterburn, et al., 2006). Throughout
this study the wide range of tissue EPA+DHA results indicate wide variations seen in
dietary regimes found within the general community from the same relative
geographical region of Melbourne (Australia), but as established in previous studies, the
principle n-3 PUFA identified in each chamber of human donor heart membrane
phospholipids is DHA, with EPA playing a minor role. There is continued conjecture as
to the minimum and maximum levels of EPA and DHA to be consumed in the diet for
achievable and adequate tissue levels for heart protection (Harris, et al., 2009; KrisEtherton, et al., 2009; Lee, et al., 2008).

4.4. CONCLUSIONS
This thesis has established that DHA is the main n-3 PUFA in human heart as it is in
animal studies, with a range that overlaps with unsupplemented and low-dose
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supplemented laboratory rat. The DHA concentration is elevated as an apparently
compensatory response to stressors and in response to dietary fish oil, as it is in animal
studies. With DHA commonly the main n-3 PUFA of table fish, but EPA the principle
n-3 PUFA provided as supplements in many clinical trials, establishing the pre-eminent
position of DHA amongst n-3 PUFA in human myocardium increases confidence in the
consistent human epidemiological studies associating usual fish consumption with
cardiovascular outcomes and in translating outcomes of animal studies to interpret
mechanisms of n-3 PUFA action in man. It also may provide some explanation for the
more variable outcomes of clinical trials.
Despite the consistent predominance of DHA over EPA and variations in their relative
concentrations in myocardium and RBC, this thesis has established that the omega-3
index provides the most robust correlations of red blood cells with human heart tissue
and can be regarded as a good indicator of myocardial membrane n-3 PUFA
composition, confirming its potential as a marker of cardiac-associated risk.

4.5. IMPLICATIONS
Human dietary intake is most often predominantly DHA (Arterburn, et al., 2006), due
to the common predominance of DHA in table fish (Kris-Etherton, et al., 2000;
Services, 2002; U.S. Department of Agriculture, 2009). However, commercial fish oil
supplements (such as menhaden oil) are most commonly rich in EPA and low in DHA.
In an extreme example, the JELIS study (Yokoyama, et al., 2007) which failed to
reduce risk of sudden death (direct cardiac effect) whilst reducing risk of new events
(coronary vascular effect) in patients post-MI, used a pure EPA supplement, in contrast
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to the GISSI-P study which prevented sudden death but not new events in a similar
clinical population using a high concentration supplement containing almost 400mg
DHA.
The present study also raises some issues relating to contradictory animal studies, which
against the backdrop of a high volume of experimental studies showing antiarrhythmic
effects of dietary fish oil found pro-arrhythmic effects of extremely high intakes of fish
oil in the dog (Billman, et al., 2012). This recent study (Billman, et al., 2012), which
found that 4g/day fish oil in the dog (equivalent to 16g/day fish oil in a 20kg man), also
revealed that the dog is a very poor incorporator of omega-3 DHA into myocardium.
With a mean DHA incorporation in unsupplemented dogs (% DHA in: RBC 0.25; right
atrium 0.38; left ventricle 0.36) well below the range observed in human hearts in this
thesis, even after 4g fish oil per day supplementation DHA incorporation remained at
the very bottom of the ranges observed in human hearts (% DHA in: RBC 2.83; right
atrium 2.71; left ventricle 2.99). Even though the rat heart can incorporate
extraordinarily high percentage of fatty acids as DHA with high fish oil supplements,
the current study has established that DHA incorporation into human heart falls into the
range of concentrations seen in hearts of unsupplemented rats or rats supplemented in
the low dose range equivalent to human intakes of 1-2 fish meals per week (Slee, et al.,
2010).

4.6. FUTURE DIRECTIONS
This project has resulted in a good body of results for the normal human heart, and has
given a view of failing myocardial phospholipid fatty acid composition. The
establishment of DHA as the principal n-3 PUFA in human heart, even after dietary
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supplementation with a predominantly EPA fish oil, may have implications for the
planning of future intervention studies and for interpretation of clinical studies, which
somewhat controversially do not always replicate the consistent human observational
studies related to usual diet.
A major limitation to this study is the lack of dietary information and fish oil
supplementation available for both heart transplant recipients and donor hearts. Donor
hearts are assumed to be influenced by normal habitual diets, but it cannot be ruled out
that heart transplant recipients have not taken oral fish oil supplements or increased
their intakes of fish in their diets; with females more likely to be taking FO
supplements. We can see however that prior cadaveric study have not included this
information and evidence from other heart stress conditions, such as that from
Benediktsdottir et al. (1988) and Gudbjarnason et al. (1975b), show our membrane
phospholipid fatty acid information follows similar patterns.

The studies presented here show limited numbers of failing (explanted) (<14%) and
donor hearts from female participants (<25%), which is a limitation to fully elucidate
the gender description of myocardial membrane phospholipid fatty acids. As observed
from numerous studies in this area, female participation is shown to be approximately
25% or less of total number of subjects which corresponds to data presented here.
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APPENDIX A. Levels of n-3 fatty acids in Australian seafood: Fatty acid composition of seafood samples.

Taken from Levels of Omega 3 fatty acids in Australian seafood. Sahar S A M Soltan PhD and Robert A Gibson PhD. Asia Pac J Clin Nutr 2008;17 (3): 385-

390.
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APPENDIX B. Amounts of omega-3 fatty acids in fish and amount of fish
consumption required to provide 1g of omega-3 per day.

Taken from Levels of Omega 3 fatty acids in Australian seafood. Sahar S A M Soltan PhD and
Robert A Gibson PhD. Asia Pac J Clin Nutr 2008;17 (3): 385-390
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APPENDIX C. SUPPLEMENTAL MATERIAL – Billman et al., 2012. Red blood cell omega-3 polyunsaturated fatty acid content
EPA
Pre
0.16 ± 0.03

Post
0.20 ± 0.03

1 g/day
(n = 7)

0.23 ± 0.05

1.22 ± 0.14*

2 g/day
(n = 12)

0.16 ± 0.02

1.66 ± 0.12*

4 g/day
(n =29)

0.20 ± 0.01

3.91 ± 0.19*

Placebo
(n = 13)

DHA
Pre
Post
0.25 ± 0.04
0.23 ± 0.04

Omega-3 Index
Pre
Post
0.40 ± 0.05
0.44 ± 0.06

#

#

0.17 ± 0.02

1.86 ± 0.17*

0.27 ± 0.08

2.01 ± 0.13*

0.23 ± 0.02

2.83 ± 0.15*

#

#

0.40 ± 0.04

3.02 ± 0.23*

0.55 ± 0.12

3.72 ± 0.22*

0.42 ± 0.03

6.76 ± 0.28*

#

#

#

#

#

All values as are mean ± SE and are expressed as % total lipid content; EPA = eicosapentaenoic acid; DHA = docasahexaenoic acid; omega-3 index =
EPA + DHA * P<0.01 Pre vs. Post; # = P<0.01 omega-3 dose vs. placebo.

ANOVA results
-6

EPA: Dose F

3/57

DHA: Dose F

-6

= 84.79, P<10 ; Pre-post, F

3/57

1/57

-6

= 52.64, P<10 ; Pre-post, F
-6

Omega-3 Index: Dose F

3/57

-6

= 196.67, P<0.10 ; Dose x Pre-post interaction, F

1/57

3/57

-6

= 228.30, P<0.10 ; Dose x Pre-post interaction, F
-6

= 101.74, P<10 ; Pre-post, F

1/57

= 81.07, P<10

3/57

-6

= 42.25, P<10
-6

= 322.22, P<0.10 ; Dose x Pre-post interaction, F

3/57

= 91.27, P<10
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APPENDIX D. SUPPLEMENTAL MATERIAL – Billman et al., 2012.
Cardiac tissue omega-3 polyunsaturated fatty acid content
Right Atrium
Placebo
(n = 12)
1 g/day
(n = 7)
2 g/day
(n = 12)
4 g/day
(n =29)
Left ventricle
Placebo
(n = 12)
1 g/day
(n = 7)
2 g/day
(n = 12)
4 g/day
(n =29)

EPA

DHA

Omega-3 Index

0.22 ± 0.08

0.38 ± 0.11

0.58 ± 0.16

1.20 ± 0.10*

3.26 ± 0.21*

4.46 ± 0.22*

1.45 ± 0.23*

2.89 ± 0.41*

4.34 ± 0.64*

2.10 ± 0.28*

2.71 ± 0.33*

4.80 ± 0.59*

0.23 ± 0.04

0.36 ± 0.07

0.59 ± 0.09

1.22 ± 0.08*

2.92 ± 0.21*

4.14 ± 0.25*

1.69 ± 0.20*

2.67 ± 0.21*

4.35 ± 0.39*

3.25 ± 0.24*

2.99 ± 0.17*

6.24 ± 0.39*

All values as are mean ± SE and are expressed as % total lipid content; EPA =
eicosapentaenoic acid; DHA = docosahexaenoic acid; omega-3 index = EPA + DHA
* P<0.01 omega-3 dose vs. placebo.

ANOVA results
Right Atrium:
EPA, F

3/56

= 7.83, P = 0.000188; DHA F

3/56

Omega-3 Index: F

3/56

= 9.51, P = 0.000036;

= 8.58, P = 0.000089

Left Ventricle:
-6

EPA, F

3/56

-6

= 30.80, P<0.10 ; DHA, F

3/56

= 36.46, P<10 ;

-6

Omega-3 Index, F

3/56

= 34.52, P<10
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APPENDIX E. Human Donor Heart Phospholipid Fatty Acid Profile

Left Atria
N

Left Ventricle

Right Atria

Right Ventricle

16

16

16

16

14:0
14:1n-7
15:0
15:1
16:0
16:1n-7
17:0
17:1n-7
18:0
18:1n-7
18:1n-9c
18:1n-9t
18:2n-6c
18:2n-6t
18:3n-3
18:3n-6
20:0
20:1n-9
20:2n-6
20:3n-3
20:3n-6
20:4n-6
20:5n-3
21:0
22:0
22:2n-6
22:4n-6
22:5n-3
22:5n-6
22:6n-3
24:0
24:1

0.41±0.07
0.03±0.03
0.09±0.07
0.08±0.14
17.53±1.43
1.52±0.83
0.25±0.09
0.40±0.39
16.15±1.70
1.94±0.33
11.51±1.69
0.13±0.07
17.41±1.97
0.02±0.03
0.13±0.07
0.005±0.01
0.11±0.05
0.30±0.24
0.12±0.06
0.05±0.04
0.77±0.15
21.54±1.62
0.63±0.31
0.07±0.04
0.13±0.08
0.01±0.03
0.48±0.20
1.98±0.45
0.31±0.14
5.17±1.51
0.12±0.02
0.37±0.04

0.38±0.08
0.006±0.02
0.11±0.05
0.02±0.08
14.46±0.60
0.61±0.50
0.26±0.05
0.31±0.49
15.76±1.60
1.60±0.35
9.71±1.35
0.26±0.12
21.64±2.04
0.10±0.22
0.21±0.07
0.005±0.01
0.10±0.05
0.27±0.08
0.08±0.05
0.05±0.04
0.83±0.17
24.44±2.13
0.75±0.39
0.07±0.04
0.19±0.09
0.02±0.04
0.48±0.16
1.94±0.43
0.36±0.13
4.42±1.23
0.12±0.01
0.29±0.03

0.52±0.13
0.00±0.00
0.10±0.08
0.01±0.03
15.64±2.87
2.48±1.19
0.29±0.07
0.05±0.12
16.78±2.27
1.92±0.39
10.77±1.89
0.01±0.03
16.67±1.34
0.03±0.07
0.08±0.08
0.03±0.07
0.11±0.17
0.31±0.22
0.07±0.07
0.02±0.04
0.78±0.12
22.52±1.91
0.74±0.30
0.04±0.05
0.12±0.16
0.06±0.14
0.68±0.18
2.15±0.41
0.43±0.15
6.12±2.08
0.11±0.03
0.34±0.05

0.39±0.08
0.002±0.00
0.10±0.05
0.03±0.07
15.18±0.81
2.05±1.80
0.30±0.06
0.02±0.04
16.55±1.32
1.63±0.20
10.10±1.60
0.24±0.14
21.58±1.86
0.01±0.02
0.02±0.04
0.01±0.01
0.12±0.06
0.38±0.24
0.10±0.04
0.03±0.04
0.79±0.13
22.20±2.36
0.61±0.32
0.06±0.05
0.20±0.12
0.01±0.03
0.48±0.12
1.75±0.46
0.37±0.13
4.06±1.13
0.13±0.01
0.30±0.03

ΣSFA
ΣMUFA
ΣPUFA

34.87±1.74
16.33±2.22
48.65±2.76

31.45±1.39
13.11±1.76
55.34±1.31

33.70±2.01
15.90±1.97
50.40±2.86

33.02±1.17
14.78±1.86
52.20±2.15

ΣPUFA n-6
ΣPUFA n-3

40.68±2.37
7.97±1.71

47.97±1.68
7.38±1.51

41.28±2.10
9.12±2.24

45.58±1.87
6.62±1.42

ΣEPA+DHA 5.81±1.74
5.17±1.56
Σ - sum of. Results are means±SD.

6.86±2.33

4.67±1.38
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APPENDIX F. Human Explanted (Failing) Heart Phospholipid Fatty Acid
Profile
Left Atria
Left Ventricle
Right Atria Right Ventricle

N

22

22

22

22

14:0
14:1n-7
15:0
15:1
16:0
16:1n-7
17:0
17:1n-7
18:0
18:1n-7
18:1n-9c
18:1n-9t
18:2n-6c
18:2n-6t
18:3n-3
18:3n-6
20:0
20:1n-9
20:2n-6
20:3n-3
20:3n-6
20:4n-6
20:5n-3
21:0
22:0
22:2n-6
22:4n-6
22:5n-3
22:5n-6
22:6n-3
24:0
24:1

0.49±0.12
0.004±0.02
0.11±0.08
0.06±0.10
18.00±1.21
1.41±1.15
0.27±0.08
0.31±0.65
16.68±1.82
2.05±0.20
12.13±1.75
0.12±0.12
18.13±2.20
0.21±0.84
0.20±0.08
0.006±0.03
0.08±0.06
0.40±0.29
0.23±0.49
0.02±0.04
0.72±0.21
19.25±2.45
0.64±0.37
0.11±0.23
0.11±0.08
0.00±0.00
0.40±0.14
1.53±0.43
0.19±0.10
5.47±1.80
0.09±0.02
0.40±0.03

0.45±0.09
0.01±0.02
0.11±0.07
0.05±0.18
15.58±1.42
1.25±0.80
0.26±0.08
0.13±0.15
17.10±1.58
1.65±0.30
10.38±1.32
0.18±0.12
20.49±2.33
0.37±1.20
0.22±0.09
0.02±0.05
0.08±0.06
0.21±0.13
0.35±0.69
0.05±0.06
0.71±0.16
21.70±3.10
0.67±0.29
0.03±0.05
0.17±0.10
0.01±0.02
0.40±0.15
1.63±0.38
0.26±0.09
4.97±1.59
0.10±0.01
0.35±0.02

0.60±0.24
0.00±0.00
0.14±0.09
0.02±0.05
16.41±2.38
2.87±1.77
0.28±0.09
0.05±0.13
15.92±1.75
1.94±0.29
12.18±1.54
0.01±0.3
17.26±2.11
0.02±0.07
0.19±0.10
0.01±0.04
0.07±0.06
0.32±0.35
0.09±0.07
0.02±0.04
0.73±0.14
20.41±2.48
0.73±0.29
0.05±0.05
0.14±0.11
0.05±0.14
0.55±0.16
1.79±0.33
0.29±0.10
6.33±1.92
0.14±0.02
0.39±0.05

0.45±0.11
0.02±0.04
0.11±0.06
0.02±0.06
16.32±1.33
1.87±1.98
0.29±0.04
0.10±0.18
17.02±1.29
1.70±0.24
10.91±1.58
0.05±0.08
20.23±2.45
0.01±0.02
0.22±0.07
0.01±0.03
0.11±0.06
0.28±0.31
0.10±0.06
0.02±0.03
0.71±0.17
20.95±2.82
0.68±0.27
0.04±0.04
0.21±0.12
0.02±0.04
0.39±0.12
1.55±0.36
0.27±0.10
4.77±1.56
0.15±0.02
0.40±0.04

ΣSFA
ΣMUFA
ΣPUFA

35.91±2.60
16.86±1.89
47.01±3.55

33.90±2.19
14.20±1.96
51.85±3.01

33.75±2.11
17.79±2.12
48.46±3.19

34.71±2.13
15.35±3.22
49.94±3.87

ΣPUFA n-6
ΣPUFA n-3

39.14±2.83
7.87±01.94

44.32±3.49
7.53±1.63

39.40±3.27
9.06±1.99

42.70±3.29
7.24±1.60

ΣEPA+DHA 6.12±2.03
5.63±1.74
Σ - sum of. Results are mean±SD.

7.06±2.11

5.46±01.71
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